Amedeo Smart

Free Medical Literature Service


 

Amedeo

Parkinson's Disease

  Free Subscription

Articles published in
Mov Disord
    March 2024
  1. LIU Y, Bainbridge J, Sillau S, Rajkovic S, et al
    Short-Term Cannabidiol with Delta-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial.
    Mov Disord. 2024 Mar 15. doi: 10.1002/mds.29768.
    >> Share

  2. FRIEDMAN JH
    A New Definition of Psychosis Is Needed in Parkinson's Disease.
    Mov Disord. 2024 Mar 14. doi: 10.1002/mds.29786.
    >> Share

  3. ZOETEWEI D, Herman T, Ginis P, Palmerini L, et al
    On-Demand Cueing for Freezing of Gait in Parkinson's Disease: A Randomized Controlled Trial.
    Mov Disord. 2024 Mar 14. doi: 10.1002/mds.29762.
    >> Share

  4. CHOUGAR L, Faucher A, Faouzi J, Lejeune FX, et al
    Contribution of MRI for the Early Diagnosis of Parkinsonism in Patients with Diagnostic Uncertainty.
    Mov Disord. 2024 Mar 14. doi: 10.1002/mds.29760.
    >> Share

  5. MENEZES JR, Nunes GA, Carra RB, da Silva Simoes J, et al
    Trans-Spinal Theta Burst Magnetic Stimulation in Parkinson's Disease and Gait Disorders.
    Mov Disord. 2024 Mar 13. doi: 10.1002/mds.29776.
    >> Share

  6. PARDO J, Montal V, Campabadal A, Oltra J, et al
    Cortical Macro- and Microstructural Changes in Parkinson's Disease with Probable Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2024 Mar 8. doi: 10.1002/mds.29761.
    >> Share

  7. SISODIA V, Malekzadeh A, Verwijk E, Schuurman PR, et al
    Bidirectional Interplay between Deep Brain Stimulation and Cognition in Parkinson's Disease: A Systematic Review.
    Mov Disord. 2024 Mar 1. doi: 10.1002/mds.29772.
    >> Share

    February 2024
  8. KRUSE C, Lipinski A, Verheyen M, Balzer-Geldsetzer M, et al
    Care of Late-Stage Parkinsonism: Resource Utilization of the Disease in Five European Countries.
    Mov Disord. 2024 Feb 29. doi: 10.1002/mds.29718.
    >> Share

  9. WILKEN M, Andres DS, Bianchi G, Hallett M, et al
    Persistence of Basal Ganglia Oscillatory Activity During Tremor Attenuation by Movement in Parkinson's Disease Patients.
    Mov Disord. 2024 Feb 28. doi: 10.1002/mds.29679.
    >> Share

  10. OJO OO, Bandres-Ciga S, Makarious MB, Crea PW, et al
    GBA1 rs3115534 Is Associated with REM Sleep Behavior Disorder in Parkinson's Disease in Nigerians.
    Mov Disord. 2024 Feb 23. doi: 10.1002/mds.29753.
    >> Share

  11. DORSEY ER, Kinel D, Pawlik ME, Zafar M, et al
    Dry-Cleaning Chemicals and a Cluster of Parkinson's Disease and Cancer: A Retrospective Investigation.
    Mov Disord. 2024 Feb 23. doi: 10.1002/mds.29723.
    >> Share

  12. AMBROSINI E, Cancilla R, Paul JJ, Bauer P, et al
    Pure Parkinsonism as Possible Phenotype Expansion of THAP1-Related Disorders.
    Mov Disord. 2024 Feb 15. doi: 10.1002/mds.29745.
    >> Share

  13. SOLIS GP, Larasati YA, Thiel M, Koval A, et al
    GNAO1 Mutations Affecting the N-Terminal alpha-Helix of Galphao Lead to Parkinsonism.
    Mov Disord. 2024 Feb 15. doi: 10.1002/mds.29720.
    >> Share

  14. PAPAGIANNAKIS N, Liu H, Koros C, Simitsi AM, et al
    Parkin mRNA Expression Levels in Peripheral Blood Mononuclear Cells in Parkin-Related Parkinson's Disease.
    Mov Disord. 2024 Feb 15. doi: 10.1002/mds.29739.
    >> Share

  15. WEINTRAUB D, Marras C, Amara A, Anderson KE, et al
    Association between Subjective Cognitive Complaints and Incident Functional Impairment in Parkinson's Disease.
    Mov Disord. 2024 Feb 6. doi: 10.1002/mds.29725.
    >> Share

  16. KULCSAROVA K, Skorvanek M
    Challenges and Future of the International Parkinson and Movement Disorder Society Prodromal Parkinson's Disease Criteria: Are We On the Right Track?
    Mov Disord. 2024 Feb 4. doi: 10.1002/mds.29724.
    >> Share

  17. YUAN X, Wan L, Chen Z, Long Z, et al
    Peripheral Inflammatory and Immune Landscape in Multiple System Atrophy: A Cross-Sectional Study.
    Mov Disord. 2024;39:391-399.
    >> Share

    January 2024
  18. FOLLETT J, Guenther D, Xoi L, Amouri R, et al
    Genetic Modifiers of LRRK2 Parkinson's Disease: A Replication Study in Arab-Berbers.
    Mov Disord. 2024 Jan 31. doi: 10.1002/mds.29735.
    >> Share

  19. MANGONE G, Tosin MHS, Goetz CG, Stebbins GT, et al
    Unveiling Assessment Gaps in Parkinson's Disease Psychosis: A Scoping Review.
    Mov Disord. 2024 Jan 30. doi: 10.1002/mds.29710.
    >> Share

  20. DAMIER P, Degos B, Castelonovo G, Anheim M, et al
    A Double-Blind, Randomized, Placebo-Controlled Trial of Bumetanide in Parkinson's Disease.
    Mov Disord. 2024 Jan 30. doi: 10.1002/mds.29726.
    >> Share

  21. MARRAS C, Fereshtehnejad SM, Berg D, Bohnen NI, et al
    Transitioning from Subtyping to Precision Medicine in Parkinson's Disease: A Purpose-Driven Approach.
    Mov Disord. 2024 Jan 20. doi: 10.1002/mds.29708.
    >> Share

  22. EIDEM LE, Birkeland E, Austdal M, Bardsen K, et al
    Fatigue in Parkinson's Disease: A Proteomic Study of Cerebrospinal Fluid.
    Mov Disord. 2024 Jan 20. doi: 10.1002/mds.29715.
    >> Share

  23. DEBOVE I, Paschen S, Amstutz D, Cardoso F, et al
    Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus.
    Mov Disord. 2024 Jan 17. doi: 10.1002/mds.29700.
    >> Share

  24. ROSE KN, Schwarzschild MA, Gomperts SN
    Clearing the Smoke: What Protects Smokers from Parkinson's Disease?
    Mov Disord. 2024 Jan 16. doi: 10.1002/mds.29707.
    >> Share

  25. MULLER S, Kassubek J, Hold ST, Kasper DC, et al
    Morbus Fabry and Parkinson's Disease-More Evidence for a Possible Genetic Link.
    Mov Disord. 2024 Jan 16. doi: 10.1002/mds.29686.
    >> Share

  26. TUNNICLIFFE L, Weil RS, Breuer J, Rodriguez-Barradas MC, et al
    Herpes Zoster and Risk of Incident Parkinson's Disease in US Veterans: A Matched Cohort Study.
    Mov Disord. 2024 Jan 16. doi: 10.1002/mds.29701.
    >> Share

  27. AMMANN C, Oliviero A, Obeso JA, Foffani G, et al
    Motor Cortex Disinhibition Is Not Associated with Freezing of Gait in Parkinson's Disease.
    Mov Disord. 2024 Jan 5. doi: 10.1002/mds.29709.
    >> Share

  28. THOMAS GEC, Hannaway N, Zarkali A, Shmueli K, et al
    Longitudinal Associations of Magnetic Susceptibility with Clinical Severity in Parkinson's Disease.
    Mov Disord. 2024 Jan 3. doi: 10.1002/mds.29702.
    >> Share

  29. SICILIANO M, Tessitore A, Morgante F, Goldman JG, et al
    Subjective Cognitive Complaints in Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Mov Disord. 2024 Jan 3. doi: 10.1002/mds.29649.
    >> Share

  30. DOMEN CH, Sillau S, Liu Y, Leehey MA, et al
    Reply to: Cognitive Safety of Cannabis Products in Parkinson's Disease: Need for Solid Scientific Evidence to Guide Clinicians and Patients Currently on Shaky Grounds.
    Mov Disord. 2024;39:222-223.
    >> Share

  31. GAN-OR Z, Alcalay RN
    Genetics of Parkinson's Disease in Underrepresented Populations: New Studies Pave the Way.
    Mov Disord. 2024;39:1-2.
    >> Share

  32. BEUDEL M
    Comment on: "A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease".
    Mov Disord. 2024;39:223-224.
    >> Share

  33. SAMPSON TR
    Circulating Extracellular Vesicles as a Potential Mediator of Synuclein Pathology in the Gut.
    Mov Disord. 2024;39:3-5.
    >> Share

  34. RAU A, Hosp JA, Rijntjes M, Weiller C, et al
    Cerebellar, Not Nigrostriatal Degeneration Impairs Dexterity in Multiple System Atrophy.
    Mov Disord. 2024;39:130-140.
    >> Share

  35. KRISMER F, Peran P, Beliveau V, Seppi K, et al
    Progressive Brain Atrophy in Multiple System Atrophy: A Longitudinal, Multicenter, Magnetic Resonance Imaging Study.
    Mov Disord. 2024;39:119-129.
    >> Share

  36. HILL ME, Johnson LA, Wang J, Escobar Sanabria D, et al
    Paradoxical Modulation of STN beta-Band Activity with Medication Compared to Deep Brain Stimulation.
    Mov Disord. 2024;39:192-197.
    >> Share

    December 2023
  37. MIRELMAN A, Volkov J, Salomon A, Gazit E, et al
    Digital Mobility Measures: A Window into Real-World Severity and Progression of Parkinson's Disease.
    Mov Disord. 2023 Dec 27. doi: 10.1002/mds.29689.
    >> Share

  38. ONG S, Funayama M, Mangyoku Y, Kawai H, et al
    Investigation of 22q11.2 Deletion in Japanese Early-Onset Parkinsonism.
    Mov Disord. 2023 Dec 25. doi: 10.1002/mds.29692.
    >> Share

  39. JANSSEN DAALEN JM, Koopman WJH, Saris CGJ, Meinders MJ, et al
    The Hypoxia Response Pathway: A Potential Intervention Target in Parkinson's Disease?
    Mov Disord. 2023 Dec 23. doi: 10.1002/mds.29688.
    >> Share

  40. BAIK K, Kim YJ, Park M, Chung SJ, et al
    Functional Brain Networks of Minor and Well-Structured Major Hallucinations in Parkinson's Disease.
    Mov Disord. 2023 Dec 22. doi: 10.1002/mds.29681.
    >> Share

  41. GONZALEZ-ROBLES C, Bartlett M, Burnell M, Clarke CS, et al
    Embedding Patient Input in Outcome Measures for Long-Term Disease-Modifying Parkinson Disease Trials.
    Mov Disord. 2023 Dec 22. doi: 10.1002/mds.29691.
    >> Share

  42. TUNOLD JA, Tan MMX, Toft M, Ross O, et al
    Lysosomal Polygenic Burden Drives Cognitive Decline in Parkinson's Disease with Low Alzheimer Risk.
    Mov Disord. 2023 Dec 20. doi: 10.1002/mds.29698.
    >> Share

  43. ESPAY AJ, Hauser RA, Dhall R, Thakkar S, et al
    Safety and Efficacy of IPX203 in Parkinson's Disease: The RISE-PD Open-Label Extension Study.
    Mov Disord. 2023 Dec 18. doi: 10.1002/mds.29685.
    >> Share

  44. MARANO M, Anzini G, Saltarocchi L, Ricciuti R, et al
    Left Vagus Stimulation Modulates Contralateral Subthalamic beta Power Improving the Gait in Parkinson's Disease.
    Mov Disord. 2023 Dec 18. doi: 10.1002/mds.29690.
    >> Share

  45. CARDOSO F, Goetz CG, Mestre TA, Sampaio C, et al
    A Statement of the MDS on Biological Definition, Staging, and Classification of Parkinson's Disease.
    Mov Disord. 2023 Dec 13. doi: 10.1002/mds.29683.
    >> Share

  46. MYLIUS V, Baars JH, Witt K, Benninger D, et al
    Deep Brain Stimulation Improves Parkinson's Disease-Associated Pain by Decreasing Spinal Nociception.
    Mov Disord. 2023 Dec 9. doi: 10.1002/mds.29666.
    >> Share

  47. KIM DJ, Isidro-Perez AL, Doering M, Llibre-Rodriguez JJ, et al
    Prevalence and Incidence of Parkinson's Disease in Latin America: A Meta-Analysis.
    Mov Disord. 2023 Dec 8. doi: 10.1002/mds.29682.
    >> Share

  48. BRISSENDEN JA, Scerbak T, Albin RL, Lee TG, et al
    Motivational Vigor in Parkinson's Disease Requires the Short and Long Duration Response to Levodopa.
    Mov Disord. 2023 Dec 7. doi: 10.1002/mds.29659.
    >> Share

  49. FIORENZATO E, Moaveninejad S, Weis L, Biundo R, et al
    Brain Dynamics Complexity as a Signature of Cognitive Decline in Parkinson's Disease.
    Mov Disord. 2023 Dec 6. doi: 10.1002/mds.29678.
    >> Share

  50. MULLER T, Kuhn W
    An Indirect Proof for Levodopa-Induced Vitamin Deficiency in Parkinson's Disease.
    Mov Disord. 2023;38:2319-2320.
    >> Share

  51. NAMBU A, Chiken S, Sano H, Hatanaka N, et al
    Dynamic Activity Model of Movement Disorders: The Fundamental Role of the Hyperdirect Pathway.
    Mov Disord. 2023;38:2145-2150.
    >> Share

  52. ZHENG Y, Cai H, Wang X, Zhang N, et al
    Erythrocytic alpha-Synuclein Species as Biomarkers for Isolated Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2023;38:2315-2317.
    >> Share

    November 2023
  53. ANDREWS SV, Kukkle PL, Menon R, Geetha TS, et al
    The Genetic Drivers of Juvenile, Young, and Early-Onset Parkinson's Disease in India.
    Mov Disord. 2023 Nov 28. doi: 10.1002/mds.29676.
    >> Share

  54. WANG J, Li H, Jia J, Shao X, et al
    Progressive Cerebrovascular Reactivity Reduction Occurs in Parkinson's Disease: A Longitudinal Study.
    Mov Disord. 2023 Nov 27. doi: 10.1002/mds.29671.
    >> Share

  55. ONGARI G, Ghezzi C, Di Martino D, Pisani A, et al
    Impaired Mitochondrial Respiration in REM-Sleep Behavior Disorder: A Biomarker of Parkinson's Disease?
    Mov Disord. 2023 Nov 25. doi: 10.1002/mds.29643.
    >> Share

  56. DI FOLCO C, Couronne R, Arnulf I, Mangone G, et al
    Charting Disease Trajectories from Isolated REM Sleep Behavior Disorder to Parkinson's Disease.
    Mov Disord. 2023 Nov 25. doi: 10.1002/mds.29662.
    >> Share


  57. Correction to Excessive alpha-beta Oscillations Mark Enlarged Motor Sign Severity and Parkinson's Disease Duration.
    Mov Disord. 2023 Nov 22. doi: 10.1002/mds.29660.
    >> Share

  58. MA DR, Li SJ, Shi JJ, Liang YY, et al
    Shared Genetic Architecture between Parkinson's Disease and Brain Structural Phenotypes.
    Mov Disord. 2023 Nov 21. doi: 10.1002/mds.29598.
    >> Share

  59. KIM A, Martinez-Valbuena I, Keith JL, Kovacs GG, et al
    Misfolded alpha-Synuclein Seeding Is Detected in Suspected LRRK2-Parkinson's Disease without Immunohistochemically Detectable alpha-Synuclein Pathology.
    Mov Disord. 2023 Nov 20. doi: 10.1002/mds.29665.
    >> Share

  60. BOOGERS A, Fasano A
    A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease.
    Mov Disord. 2023 Nov 15. doi: 10.1002/mds.29656.
    >> Share

  61. KERESTES R, Laansma MA, Owens-Walton C, Perry A, et al
    Cerebellar Volume and Disease Staging in Parkinson's Disease: An ENIGMA-PD Study.
    Mov Disord. 2023 Nov 14. doi: 10.1002/mds.29611.
    >> Share

  62. OERTEL WH, Paule E, Hasemann T, Sittig E, et al
    Reduced Gastric Contraction in Rapid-Eye-Movement Sleep Behavior Disorder and De Novo Parkinson's Disease.
    Mov Disord. 2023 Nov 13. doi: 10.1002/mds.29652.
    >> Share

  63. KONERU V, Espay AJ, Cole AJ, Weintraub D, et al
    The Self-Administered Screening Questionnaire for Parkinson's Disease-Associated Psychosis (SASPAP).
    Mov Disord. 2023 Nov 8. doi: 10.1002/mds.29627.
    >> Share

  64. DAIDA K, Funayama M, Billingsley KJ, Malik L, et al
    Long-Read Sequencing Resolves a Complex Structural Variant in PRKN Parkinson's Disease.
    Mov Disord. 2023 Nov 5. doi: 10.1002/mds.29610.
    >> Share

  65. SAFFIE AWAD P, Teixeira-Dos-Santos D, Santos-Lobato BL, Camargos S, et al
    Frequency of Hereditary and GBA1-Related Parkinsonism in Latin America: A Systematic Review and Meta-Analysis.
    Mov Disord. 2023 Nov 3. doi: 10.1002/mds.29614.
    >> Share

  66. PAL GD, Corcos DM, Metman LV, Israel Z, et al
    Cognitive Effects of Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease with GBA1 Pathogenic Variants.
    Mov Disord. 2023 Nov 2. doi: 10.1002/mds.29647.
    >> Share


  67. The Future of Parkinson's Disease: Improving Care & Driving Research.
    Mov Disord. 2023;38 Suppl 2:S1-S21.
    >> Share

  68. BERGER SL, Seemiller J, Rosenthal LS
    Synuclein Seed Amplification in the Cerebrospinal Fluid: Research and Clinical Implications.
    Mov Disord. 2023;38:1990-1991.
    >> Share

  69. VASILEVSKAYA A, Martinez-Valbuena I, Anastassiadis C, Taghdiri F, et al
    Misfolded alpha-Synuclein in Cerebrospinal Fluid of Contact Sport Athletes.
    Mov Disord. 2023;38:2125-2131.
    >> Share

  70. DI LUCA DG, Ramirez-Gomez C, Germann J, Santyr B, et al
    Deep Brain Stimulation of the Globus Pallidus Internus and Externus in Multiple System Atrophy.
    Mov Disord. 2023;38:2121-2125.
    >> Share

    October 2023
  71. OLANOW CW, Hauser RA, Burdick DJ, Dhall R, et al
    A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease.
    Mov Disord. 2023 Oct 27. doi: 10.1002/mds.29642.
    >> Share

  72. PAHWA R, Merola A, Soileau M, Alobaidi A, et al
    Cost-Effectiveness of Carbidopa-Levodopa Enteral Suspension for Advanced Parkinson's Disease in the United States.
    Mov Disord. 2023 Oct 25. doi: 10.1002/mds.29624.
    >> Share

  73. BOUGOU V, Vanhoyland M, Decramer T, Van Hoylandt A, et al
    Active and Passive Cycling Decrease Subthalamic beta Oscillations in Parkinson's Disease.
    Mov Disord. 2023 Oct 20. doi: 10.1002/mds.29632.
    >> Share

  74. CONTI M, Guerra A, Pierantozzi M, Bovenzi R, et al
    Band-Specific Altered Cortical Connectivity in Early Parkinson's Disease and its Clinical Correlates.
    Mov Disord. 2023 Oct 20. doi: 10.1002/mds.29615.
    >> Share

  75. ALBIN R, Grotewold N
    What is the Parkinson Pandemic?
    Mov Disord. 2023 Oct 20. doi: 10.1002/mds.29637.
    >> Share

  76. WOO KA, Joun JH, Yoon EJ, Lee CY, et al
    Monoaminergic Degeneration and Ocular Motor Abnormalities in De Novo Parkinson's Disease.
    Mov Disord. 2023 Oct 17. doi: 10.1002/mds.29623.
    >> Share

  77. BUSCH JL, Kaplan J, Bahners BH, Roediger J, et al
    Local Field Potentials Predict Motor Performance in Deep Brain Stimulation for Parkinson's Disease.
    Mov Disord. 2023 Oct 12. doi: 10.1002/mds.29626.
    >> Share

  78. SAMUEL N, Ding MYR, Sarica C, Darmani G, et al
    Accelerated Transcranial Ultrasound Neuromodulation in Parkinson's Disease: A Pilot Study.
    Mov Disord. 2023 Oct 9. doi: 10.1002/mds.29622.
    >> Share

  79. YANG Y, Stewart T, Zhang C, Wang P, et al
    Erythrocytic alpha-Synuclein and the Gut Microbiome: Kindling of the Gut-Brain Axis in Parkinson's Disease.
    Mov Disord. 2023 Oct 5. doi: 10.1002/mds.29620.
    >> Share

  80. WAN L, Fu Y, Chen Z, Long Z, et al
    No Correlation between Plasma GPNMB Levels and Multiple System Atrophy in Chinese Cohorts.
    Mov Disord. 2023;38:1956-1961.
    >> Share

  81. HU Y, Ma TC, Alberico SL, Ding Y, et al
    Substantia Nigra Pars Reticulata Projections to the Pedunculopontine Nucleus Modulate Dyskinesia.
    Mov Disord. 2023;38:1850-1860.
    >> Share

  82. GROSSMANN D, Malburg N, Glass H, Weeren V, et al
    Mitochondria-Endoplasmic Reticulum Contact Sites Dynamics and Calcium Homeostasis Are Differentially Disrupted in PINK1-PD or PRKN-PD Neurons.
    Mov Disord. 2023;38:1822-1836.
    >> Share

    September 2023
  83. JANSSEN DAALEN JM, Oosterhof TH, Bloem BR, Darweesh SKL, et al
    Wearables for Parkinson's: Fast-Paced toward Novel Outcome Measures.
    Mov Disord. 2023 Sep 29. doi: 10.1002/mds.29608.
    >> Share

  84. SATOH R, Weigand SD, Pham NTT, Ali F, et al
    Magnetic Susceptibility in Progressive Supranuclear Palsy Variants, Parkinson's Disease, and Corticobasal Syndrome.
    Mov Disord. 2023 Sep 29. doi: 10.1002/mds.29613.
    >> Share

  85. DI FONZO A, Percetti M, Monfrini E, Palmieri I, et al
    Harmonizing Genetic Testing for Parkinson's Disease: Results of the PARKNET Multicentric Study.
    Mov Disord. 2023 Sep 26. doi: 10.1002/mds.29617.
    >> Share

  86. TOFFOLI M, Schapira AHV, Proukakis C
    Sex Distribution of GBA1 Variants Carriers with Dementia with Lewy Bodies and Parkinson's Disease.
    Mov Disord. 2023 Sep 22. doi: 10.1002/mds.29609.
    >> Share

  87. NATALE G, Colella M, De Carluccio M, Lelli D, et al
    Astrocyte Responses Influence Local Effects of Whole-Brain Magnetic Stimulation in Parkinsonian Rats.
    Mov Disord. 2023 Sep 12. doi: 10.1002/mds.29599.
    >> Share

  88. ZHAO Y, Ray A, Broberg K, Kippler M, et al
    Prediagnostic Blood Metal Levels and the Risk of Parkinson's Disease: A Large European Prospective Cohort.
    Mov Disord. 2023 Sep 7. doi: 10.1002/mds.29602.
    >> Share

  89. BOOIJ J, Tellier SP, Seibyl J, Vriend C, et al
    Dopamine Transporter Availability in Early Parkinson's Disease is Dependent on Sunlight Exposure.
    Mov Disord. 2023 Sep 5. doi: 10.1002/mds.29597.
    >> Share

  90. MARKAKI I, Paslawski W, Ntetsika T, Engesvik L, et al
    Isolation of L1CAM-Extracellular Vesicles Reveals Signs of Insulin Resistance in Parkinson's Disease.
    Mov Disord. 2023 Sep 5. doi: 10.1002/mds.29601.
    >> Share


  91. Correction to "Olfactory Neuron Substance P Is Overexpressed in Parkinson's Disease Reflecting Gut Dysfunction".
    Mov Disord. 2023 Sep 5. doi: 10.1002/mds.29600.
    >> Share

  92. FINK A, Dodel R, Georges D, Doblhammer G, et al
    The Impact of Sex-Specific Survival on the Incidence of Dementia in Parkinson's Disease.
    Mov Disord. 2023 Sep 1. doi: 10.1002/mds.29596.
    >> Share

  93. BOON LI, Buijink AWG
    Parkinsonian Tremor: Shaking in Synchrony.
    Mov Disord. 2023;38:1582-1584.
    >> Share

  94. GONZALEZ-LATAPI P, Lo RY
    Bone First or Brain First: "Picking at the Bones" of Parkinson's Disease.
    Mov Disord. 2023;38:1579-1581.
    >> Share

  95. ZHANG D, Zhou L, Yao J, Shi Y, et al
    Increased Free Water in the Putamen in Idiopathic REM Sleep Behavior Disorder.
    Mov Disord. 2023;38:1645-1654.
    >> Share

    August 2023
  96. SUN H, Gan C, Wang L, Ji M, et al
    Cortical Disinhibition Drives Freezing of Gait in Parkinson's Disease and an Exploratory Repetitive Transcranial Magnetic Stimulation Study.
    Mov Disord. 2023 Aug 30. doi: 10.1002/mds.29595.
    >> Share

  97. TOTSUNE T, Baba T, Sugimura Y, Oizumi H, et al
    Nuclear Imaging Data-Driven Classification of Parkinson's Disease.
    Mov Disord. 2023 Aug 28. doi: 10.1002/mds.29582.
    >> Share

  98. WEINTRAUB D
    What's in a Name? The Time Has Come to Unify Parkinson's Disease and Dementia with Lewy Bodies.
    Mov Disord. 2023 Aug 23. doi: 10.1002/mds.29590.
    >> Share

  99. ANDICA C, Kamagata K, Uchida W, Saito Y, et al
    Fiber-Specific White Matter Alterations in Parkinson's Disease Patients with GBA Gene Mutations.
    Mov Disord. 2023 Aug 22. doi: 10.1002/mds.29578.
    >> Share

  100. PARK KY, Jung JH, Hwang HS, Park HK, et al
    Bone Mineral Density and the Risk of Parkinson's Disease in Postmenopausal Women.
    Mov Disord. 2023 Aug 21. doi: 10.1002/mds.29579.
    >> Share

  101. TRESSERRA-RIMBAU A, Thompson AS, Bondonno N, Jennings A, et al
    Plant-Based Dietary Patterns and Parkinson's Disease: A Prospective Analysis of the UK Biobank.
    Mov Disord. 2023 Aug 21. doi: 10.1002/mds.29580.
    >> Share

  102. DAI L, Wang J, Zhang X, Yan M, et al
    27-Hydroxycholesterol Drives the Spread of alpha-Synuclein Pathology in Parkinson's Disease.
    Mov Disord. 2023 Aug 18. doi: 10.1002/mds.29577.
    >> Share

  103. BAR-ON M, Baharav S, Katzir Z, Mirelman A, et al
    Task-Related Reorganization of Cognitive Network in Parkinson's Disease Using Electrophysiology.
    Mov Disord. 2023 Aug 8. doi: 10.1002/mds.29571.
    >> Share

  104. GAARE JJ, Brugger K, Nido GS, Tzoulis C, et al
    DNA Methylation Age Acceleration Is Not Associated with Age of Onset in Parkinson's Disease.
    Mov Disord. 2023 Aug 7. doi: 10.1002/mds.29574.
    >> Share

  105. CHU Y, Kordower JH
    Post-Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10 Years CERE120 Delivery.
    Mov Disord. 2023 Aug 6. doi: 10.1002/mds.29518.
    >> Share

  106. TA M, Blauwendraat C, Antar T, Leonard HL, et al
    Genome-Wide Meta-Analysis of Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Parkinson's Disease Cohorts.
    Mov Disord. 2023 Aug 4. doi: 10.1002/mds.29511.
    >> Share

  107. CHUA MMJ, Blitz SE, Ng PR, Segar DJ, et al
    Focused Ultrasound Thalamotomy for Tremor in Parkinson's Disease: Outcomes in a Large, Prospective Cohort.
    Mov Disord. 2023 Aug 4. doi: 10.1002/mds.29569.
    >> Share

  108. TIAN Y, Ma G, Li H, Zeng Y, et al
    Shared Genetics and Comorbid Genes of Amyotrophic Lateral Sclerosis and Parkinson's Disease.
    Mov Disord. 2023 Aug 3. doi: 10.1002/mds.29572.
    >> Share

  109. AQUINO C, Luo L, Agarwal P, Garg K, et al
    Deep Brain Stimulation as an Exclusion Criteria in Parkinson's Disease Studies: Time to Rethink?
    Mov Disord. 2023 Aug 2. doi: 10.1002/mds.29554.
    >> Share

  110. VIRAMETEEKUL S, de Pablo-Fernandez E
    Variability in the Accuracy of Clinical Diagnosis of Early Parkinson's Disease.
    Mov Disord. 2023;38:1574-1575.
    >> Share

  111. GOETZ CG, Zou H, Stebbins GT, Schrag A, et al
    Reply to: Comment on "Summing MDS-UPDRS Parts 1 + 2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice".
    Mov Disord. 2023;38:1564.
    >> Share

  112. KOVACS N, Aschermann Z, Harmat M, Rohonczi M, et al
    Comment on "Summing MDS-UPDRS Parts 1 + 2 (Nonmotor and Motor Experience of Daily Living): The Patient's Voice".
    Mov Disord. 2023;38:1563-1564.
    >> Share

  113. BEACH TG, Adler CH, Shill HA, Zhang N, et al
    Accuracy of the Early Diagnosis of Parkinson's Disease.
    Mov Disord. 2023;38:1573-1574.
    >> Share

  114. KLIETZ M, Mahmoudi N, Maudsley AA, Sheriff S, et al
    Whole-Brain Magnetic Resonance Spectroscopy Reveals Distinct Alterations in Neurometabolic Profile in Progressive Supranuclear Palsy.
    Mov Disord. 2023;38:1503-1514.
    >> Share

  115. AGIN-LIEBES J, Hickman RA, Vonsattel JP, Faust PL, et al
    Patterns of TDP-43 Deposition in Brains with LRRK2 G2019S Mutations.
    Mov Disord. 2023;38:1541-1545.
    >> Share


  116. Abstracts of the 2023 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2023;38 Suppl 1:S1-S871.
    >> Share

  117. ALBANESE A, Bhatia KP, Cardoso F, Comella C, et al
    Isolated Cervical Dystonia: Diagnosis and Classification.
    Mov Disord. 2023;38:1367-1378.
    >> Share

    July 2023
  118. LABRADOR-ESPINOSA MA, Silva-Rodriguez J, Reina-Castillo MI, Mir P, et al
    Basal Forebrain Atrophy, Cortical Thinning, and Amyloid-beta Status in Parkinson's disease-Related Cognitive Decline.
    Mov Disord. 2023 Jul 26. doi: 10.1002/mds.29564.
    >> Share

  119. BORSCHE M, Berg D
    Blood-Based alpha-Synuclein Seeding-A New Era for Identifying Parkinsonian Syndromes.
    Mov Disord. 2023 Jul 25. doi: 10.1002/mds.29555.
    >> Share

  120. JEONG SH, Kim SH, Park CW, Lee HS, et al
    Differential Implications of Cerebral Hypoperfusion and Hyperperfusion in Parkinson's Disease.
    Mov Disord. 2023 Jul 25. doi: 10.1002/mds.29565.
    >> Share

  121. LUTH T, Gabbert C, Koch S, Konig IR, et al
    Interaction of Mitochondrial Polygenic Score and Lifestyle Factors in LRRK2 p.Gly2019Ser Parkinsonism.
    Mov Disord. 2023 Jul 21. doi: 10.1002/mds.29563.
    >> Share

  122. LEAL TP, Rao SC, French-Kwawu JN, Gouveia MH, et al
    X-Chromosome Association Study in Latin American Cohorts Identifies New Loci in Parkinson's Disease.
    Mov Disord. 2023 Jul 20. doi: 10.1002/mds.29508.
    >> Share

  123. XYLAKI M, Chopra A, Weber S, Bartl M, et al
    Extracellular Vesicles for the Diagnosis of Parkinson's Disease: Systematic Review and Meta-Analysis.
    Mov Disord. 2023 Jul 14. doi: 10.1002/mds.29497.
    >> Share

  124. TESSON C, Bouchetara MS, Ferrien M, Lesage S, et al
    Identification of a DAGLB Mutation in a Non-Chinese Patient with Parkinson's Disease.
    Mov Disord. 2023 Jul 11. doi: 10.1002/mds.29533.
    >> Share

  125. ZHUPARRIS A, Thijssen E, Elzinga WO, Makai-Boloni S, et al
    Treatment Detection and Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Part III Estimation Using Finger Tapping Tasks.
    Mov Disord. 2023 Jul 4. doi: 10.1002/mds.29520.
    >> Share

  126. ARSHAD U, Rahman F, Hanan N, Chen C, et al
    Longitudinal Meta-Analysis of Historical Parkinson's Disease Trials to Inform Future Trial Design.
    Mov Disord. 2023 Jul 3. doi: 10.1002/mds.29514.
    >> Share

  127. TURNER TH, Hinson VK
    Cognitive Safety of Cannabis Products in Parkinson's Disease: Need for Solid Scientific Evidence to Guide Clinicians and Patients Currently on Shaky Grounds.
    Mov Disord. 2023;38:1125-1126.
    >> Share

  128. PU J, Lin L, Jiang H, Hu Z, et al
    Parkin Maintains Robust Pacemaking in Human Induced Pluripotent Stem Cell-Derived A9 Dopaminergic Neurons.
    Mov Disord. 2023;38:1273-1281.
    >> Share

  129. ZOU H, Goetz CG, Stebbins GT, Schrag A, et al
    Summing MDS-UPDRS Parts 1 + 2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice.
    Mov Disord. 2023;38:1363-1364.
    >> Share

    June 2023
  130. SCHLIESSER P, Struebing FL, Northoff BH, Kurz A, et al
    Detection of a Parkinson's Disease-Specific MicroRNA Signature in Nasal and Oral Swabs.
    Mov Disord. 2023 Jun 29. doi: 10.1002/mds.29515.
    >> Share

  131. VON BELOW D, Wallerstedt SM, Bergquist F
    Validation of the Swedish Patient-Reported Outcomes in Parkinson's Disease Scale in Outpatients.
    Mov Disord. 2023 Jun 29. doi: 10.1002/mds.29517.
    >> Share

  132. SENKEVICH K, Beletskaia M, Dworkind A, Yu E, et al
    Association of Rare Variants in ARSA with Parkinson's Disease.
    Mov Disord. 2023 Jun 28. doi: 10.1002/mds.29521.
    >> Share

  133. PAL G, Cook L, Schulze J, Verbrugge J, et al
    Genetic Testing in Parkinson's Disease.
    Mov Disord. 2023 Jun 27. doi: 10.1002/mds.29500.
    >> Share

  134. DIRKX MF, Shine JM, Helmich RC
    Integrative Brain States Facilitate the Expression of Parkinson's Tremor.
    Mov Disord. 2023 Jun 26. doi: 10.1002/mds.29506.
    >> Share

  135. VENUTO CS, Smith G, Herbst K, Zielinski R, et al
    Predicting Ambulatory Capacity in Parkinson's Disease to Analyze Progression, Biomarkers, and Trial Design.
    Mov Disord. 2023 Jun 26. doi: 10.1002/mds.29519.
    >> Share

  136. LIN CP, Knoop LEJ, Frigerio I, Bol JGJM, et al
    Nigral Pathology Contributes to Microstructural Integrity of Striatal and Frontal Tracts in Parkinson's Disease.
    Mov Disord. 2023 Jun 22. doi: 10.1002/mds.29510.
    >> Share

  137. SICILIANO M, De Micco R, Russo AG, Esposito F, et al
    Memory Phenotypes In Early, De Novo Parkinson's Disease Patients with Mild Cognitive Impairment.
    Mov Disord. 2023 Jun 15. doi: 10.1002/mds.29502.
    >> Share

  138. HAMEDANI AG, Auinger P, Willis AW, Safarpour D, et al
    Adjusting for Underrepresentation Reveals Widespread Underestimation of Parkinson's Disease Symptom Burden.
    Mov Disord. 2023 Jun 15. doi: 10.1002/mds.29507.
    >> Share

  139. SIMONET C, Mahlknecht P, Marini K, Seppi K, et al
    The Emergence and Progression of Motor Dysfunction in Individuals at Risk of Parkinson's Disease.
    Mov Disord. 2023 Jun 15. doi: 10.1002/mds.29496.
    >> Share

  140. FLORES-TORRES MH, Bjornevik K, Hung AY, Healy BC, et al
    Subjective Cognitive Decline in Women with Features Suggestive of Prodromal Parkinson's Disease.
    Mov Disord. 2023 Jun 14. doi: 10.1002/mds.29503.
    >> Share

  141. YASSINE S, Gschwandtner U, Auffret M, Duprez J, et al
    Identification of Parkinson's Disease Subtypes from Resting-State Electroencephalography.
    Mov Disord. 2023 Jun 13. doi: 10.1002/mds.29451.
    >> Share

  142. SAUNDERS-PULLMAN R, Raymond D, Ortega RA, Shalash A, et al
    International Genetic Testing and Counseling Practices for Parkinson's Disease.
    Mov Disord. 2023 Jun 13. doi: 10.1002/mds.29442.
    >> Share

  143. SCOTT GD, Neilson LE, Woltjer R, Quinn JF, et al
    Lifelong Association of Disorders Related to Military Trauma with Subsequent Parkinson's Disease.
    Mov Disord. 2023 Jun 13. doi: 10.1002/mds.29457.
    >> Share

  144. GILES DORAN C, Wilson F, Goulding SR, Mazzocchi M, et al
    Bioinformatics and Immunohistochemical Analyses Support Preserved Expression of Glial Cell Line-Derived Neurotrophic Factor Receptor RET in Parkinson's.
    Mov Disord. 2023;38:1115-1116.
    >> Share

  145. WHONE A
    Reply to: "Bioinformatics and Immunohistochemistry Show Preserved Expression of GDNF Receptor RET in Parkinson's".
    Mov Disord. 2023;38:1117-1118.
    >> Share

  146. PAL GD, David FJ, Shils JL, Munoz MJ, et al
    Subthalamic Physiology in Genetic Subtypes of Parkinson's Disease.
    Mov Disord. 2023;38:1113-1114.
    >> Share

  147. WEILL C, Gallant A, Baker Erdman H, Abu Snineh M, et al
    Reply to: "Subthalamic Physiology in Genetic Subtypes of Parkinson's Disease".
    Mov Disord. 2023;38:1114.
    >> Share

  148. NEUMANN WJ, Gilron R, Little S, Tinkhauser G, et al
    Adaptive Deep Brain Stimulation: From Experimental Evidence Toward Practical Implementation.
    Mov Disord. 2023;38:937-948.
    >> Share

  149. MARTINO D, Karnik V, Bhidayasiri R, Hall DA, et al
    Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations.
    Mov Disord. 2023;38:1008-1026.
    >> Share

  150. SCHIDLITZKI A, Stanojlovic M, Fournier C, Kaufer C, et al
    Double-Edged Effects of Venglustat on Behavior and Pathology in Mice Overexpressing alpha-Synuclein.
    Mov Disord. 2023;38:1044-1055.
    >> Share

  151. STEFANI A, Serradell M, Holzknecht E, Gaig C, et al
    Low Specificity of Rapid Eye Movement Sleep Behavior Disorder Questionnaires: Need for Better Screening Methods.
    Mov Disord. 2023;38:1000-1007.
    >> Share

  152. UEDA J, Uemura N, Ishimoto T, Taguchi T, et al
    Ca(2+) -Calmodulin-Calcineurin Signaling Modulates alpha-Synuclein Transmission.
    Mov Disord. 2023;38:1056-1067.
    >> Share

  153. PEREZ-CARBONELL L, Simonet C, Chohan H, Gill A, et al
    The Views of Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder on Risk Disclosure.
    Mov Disord. 2023;38:1089-1093.
    >> Share

  154. KUZKINA A, Panzer C, Seger A, Schmitt D, et al
    Dermal Real-Time Quaking-Induced Conversion Is a Sensitive Marker to Confirm Isolated Rapid Eye Movement Sleep Behavior Disorder as an Early alpha-Synucleinopathy.
    Mov Disord. 2023;38:1077-1082.
    >> Share

    May 2023
  155. PAYNE T, Appleby M, Buckley E, van Gelder LMA, et al
    A Double-Blind, Randomized, Placebo-Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease.
    Mov Disord. 2023 May 29. doi: 10.1002/mds.29450.
    >> Share

  156. GEORGIADES MJ, Shine JM, Gilat M, McMaster J, et al
    Subthalamic Nucleus Activity during Cognitive Load and Gait Dysfunction in Parkinson's Disease.
    Mov Disord. 2023 May 25. doi: 10.1002/mds.29455.
    >> Share

  157. DOMEN CH, Sillau S, Liu Y, Adkins M, et al
    Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and Delta9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms.
    Mov Disord. 2023 May 22. doi: 10.1002/mds.29447.
    >> Share

  158. HUTTUNEN HJ, Booms S, Sjogren M, Kerstens V, et al
    Intraputamenal Cerebral Dopamine Neurotrophic Factor in Parkinson's Disease: A Randomized, Double-Blind, Multicenter Phase 1 Trial.
    Mov Disord. 2023 May 22. doi: 10.1002/mds.29426.
    >> Share

  159. KROSCHE M, Kannenberg S, Butz M, Hartmann CJ, et al
    Slowing of Frontal beta Oscillations in Atypical Parkinsonism.
    Mov Disord. 2023 May 20. doi: 10.1002/mds.29378.
    >> Share

  160. DEN HEIJER JM, Kruithof AC, Moerland M, Walker M, et al
    A Phase 1B Trial in GBA1-Associated Parkinson's Disease of BIA-28-6156, a Glucocerebrosidase Activator.
    Mov Disord. 2023 May 17. doi: 10.1002/mds.29346.
    >> Share

  161. RAFEE S, Fearon C
    Palmitoylation: A New Therapeutic Target for Parkinson's Disease?
    Mov Disord. 2023 May 11. doi: 10.1002/mds.29418.
    >> Share

  162. MAMARIL-DAVIS JC, Gelb AW, Larson PS
    Procedure-Related Complications in Sham Surgeries for Parkinson's Clinical Trials: A Meta-analysis.
    Mov Disord. 2023 May 11. doi: 10.1002/mds.29406.
    >> Share

  163. SCHIRINZI T, Maftei D, Grillo P, Bovenzi R, et al
    Olfactory Neuron Substance P is Overexpressed in Parkinson's Disease Reflecting Gut Dysfunction.
    Mov Disord. 2023 May 8. doi: 10.1002/mds.29433.
    >> Share

  164. BROWN GC, Camacho M, Williams-Gray CH
    The Endotoxin Hypothesis of Parkinson's Disease.
    Mov Disord. 2023 May 8. doi: 10.1002/mds.29432.
    >> Share

  165. RYMAN SG, Shaff N, Dodd A, Nitschke S, et al
    Reduced and Delayed Cerebrovascular Reactivity in Patients with Parkinson's Disease.
    Mov Disord. 2023 May 8. doi: 10.1002/mds.29429.
    >> Share

  166. OUTEIRO TF, Alcalay RN, Antonini A, Attems J, et al
    Defining the Riddle in Order to Solve It: There Is More Than One "Parkinson's Disease".
    Mov Disord. 2023 May 8. doi: 10.1002/mds.29419.
    >> Share

  167. KOROS C, Brockmann K, Simitsi AM, Bougea A, et al
    Impact of APOE Genotype on Cognition in Idiopathic and Genetic Forms of Parkinson's Disease.
    Mov Disord. 2023 May 6. doi: 10.1002/mds.29399.
    >> Share

  168. SENKEVICH K, Alipour P, Chernyavskaya E, Yu E, et al
    Potential Protective Link Between Type I Diabetes and Parkinson's Disease Risk and Progression.
    Mov Disord. 2023 May 6. doi: 10.1002/mds.29424.
    >> Share

  169. VALENTIJN PP, Eggers C, Bloem BR, Grimes D, et al
    Validation of the Rainbow Model of Integrated Care Measurement Tool in Parkinson's Disease.
    Mov Disord. 2023 May 6. doi: 10.1002/mds.29413.
    >> Share

  170. NG J, Barral S, Waddington SN, Kurian MA, et al
    Gene Therapy for Dopamine Dyshomeostasis: From Parkinson's to Primary Neurotransmitter Diseases.
    Mov Disord. 2023 May 5. doi: 10.1002/mds.29416.
    >> Share

  171. JOST ST, Kaldenbach MA, Antonini A, Martinez-Martin P, et al
    Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals.
    Mov Disord. 2023 May 5. doi: 10.1002/mds.29410.
    >> Share

  172. AVERNA A, Debove I, Nowacki A, Peterman K, et al
    Spectral Topography of the Subthalamic Nucleus to Inform Next-Generation Deep Brain Stimulation.
    Mov Disord. 2023;38:818-830.
    >> Share

  173. LOFREDI R, Scheller U, Mindermann A, Feldmann LK, et al
    Pallidal Beta Activity Is Linked to Stimulation-Induced Slowness in Dystonia.
    Mov Disord. 2023;38:894-899.
    >> Share

  174. ZHANG D, Shi Y, Yao J, Zhou L, et al
    Free-Water Imaging of the Substantia Nigra in GBA Pathogenic Variant Carriers.
    Mov Disord. 2023;38:764-773.
    >> Share

    April 2023
  175. MESTRE TA, McDermott MP, Lobo R, Ferreira JJ, et al
    The Lessebo Effect in Disease Modification Trials in Parkinson's Disease.
    Mov Disord. 2023 Apr 24. doi: 10.1002/mds.29414.
    >> Share

  176. GEROIN C, Artusi CA, Nonnekes J, Aquino C, et al
    Axial Postural Abnormalities in Parkinsonism: Gaps in Predictors, Pathophysiology, and Management.
    Mov Disord. 2023 Apr 20. doi: 10.1002/mds.29377.
    >> Share

  177. LI C, Lin J, Jiang Q, Yang T, et al
    Cross-Ethnic Variant Screening and Burden Analysis of PTPA in Parkinson's Disease.
    Mov Disord. 2023 Apr 12. doi: 10.1002/mds.29411.
    >> Share

  178. OH YS, Kim JS, Lyoo CH, Kim H, et al
    Obstructive Sleep Apnea and Striatal Dopamine Availability in Parkinson's Disease.
    Mov Disord. 2023 Apr 12. doi: 10.1002/mds.29402.
    >> Share

  179. BELOVA E, Semenova U, Gamaleya A, Tomskiy A, et al
    Excessive alpha-beta Oscillations Mark Enlarged Motor Sign Severity and Parkinson's Disease Duration.
    Mov Disord. 2023 Apr 6. doi: 10.1002/mds.29393.
    >> Share

  180. MULLER T, Kuhn W
    Epigenetic Drug Effects in Levodopa-Treated Patients with Parkinson's Disease.
    Mov Disord. 2023;38:710-711.
    >> Share

  181. THALER A, Mirelman A, Alcalay RN
    Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism.
    Mov Disord. 2023;38:713-714.
    >> Share

  182. YANG X, Xiao Q
    Reply to: "Epigenetic Drug Effects in Levodopa Treated Patients with Parkinson's Disease".
    Mov Disord. 2023;38:711.
    >> Share

  183. LANG AE
    Targeting alpha-Synuclein: A Further Viewpoint.
    Mov Disord. 2023;38:715-716.
    >> Share

  184. POSTUMA RB, Lang AE
    The Clinical Diagnosis of Parkinson's Disease-We Are Getting Better.
    Mov Disord. 2023;38:515-517.
    >> Share

  185. ORTEGA RA, Bressman SB, Raymond D, Ozelius LJ, et al
    Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism.
    Mov Disord. 2023;38:714-715.
    >> Share

  186. PERCETTI M, Monfrini E, Caporali L, Minardi R, et al
    Reply to: "Lack of Association between TWNK Rare Variants and Parkinson's Disease in a Chinese Cohort".
    Mov Disord. 2023;38:709-710.
    >> Share

  187. KRESOJEVIC N, Markovic V, Dobricic V, Stankovic I, et al
    Reply to: "Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism".
    Mov Disord. 2023;38:712-713.
    >> Share

  188. LI C, Lin J, Jiang Q, Yang T, et al
    Lack of Association between TWNK Rare Variants and Parkinson's Disease in a Chinese Cohort.
    Mov Disord. 2023;38:708-709.
    >> Share

  189. BOLOGNA M, Espay AJ, Fasano A, Paparella G, et al
    Redefining Bradykinesia.
    Mov Disord. 2023;38:551-557.
    >> Share

  190. HUANG SY, Chen SF, Cui M, Zhao M, et al
    Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy.
    Mov Disord. 2023;38:676-682.
    >> Share

    March 2023
  191. BORSCHE M, Pratuseviciute N, Schaake S, Hinrichs F, et al
    The New p.F1700L LRRK2 Variant Causes Parkinson's Disease by Extensively Increasing Kinase Activity.
    Mov Disord. 2023 Mar 27. doi: 10.1002/mds.29385.
    >> Share

  192. ZENG R, Wang J, Zheng C, Jiang R, et al
    Lack of Causal Associations of Inflammatory Bowel Disease with Parkinson's Disease and Other Neurodegenerative Disorders.
    Mov Disord. 2023 Mar 23. doi: 10.1002/mds.29386.
    >> Share

  193. ZHOU G, Ren J, Rong D, Zhou H, et al
    Monitoring Substantia Nigra Degeneration Using Free Water Imaging across Prodromal and Clinical Parkinson's Disease.
    Mov Disord. 2023 Mar 22. doi: 10.1002/mds.29366.
    >> Share

  194. MESTRE TA, Schlossmacher MG
    Target-Specific Strategies to Modify the Course of Parkinson's: Is Iron Chelation Safe?
    Mov Disord. 2023 Mar 21. doi: 10.1002/mds.29382.
    >> Share

  195. FLORES-TORRES MH, Christine CW, Bjornevik K, Molsberry SA, et al
    Long-Term Intake of Folate, Vitamin B6, and Vitamin B12 and the Incidence of Parkinson's Disease in a Sample of U.S. Women and Men.
    Mov Disord. 2023 Mar 20. doi: 10.1002/mds.29383.
    >> Share

  196. DEN HEIJER JM, Cullen VC, Pereira DR, Yavuz Y, et al
    A Biomarker Study in Patients with GBA1-Parkinson's Disease and Healthy Controls.
    Mov Disord. 2023 Mar 14. doi: 10.1002/mds.29360.
    >> Share

  197. MUNOZ-DELGADO L, Labrador-Espinosa MA, Macias-Garcia D, Jesus S, et al
    Peripheral Inflammation Is Associated with Dopaminergic Degeneration in Parkinson's Disease.
    Mov Disord. 2023 Mar 13. doi: 10.1002/mds.29369.
    >> Share

  198. KAMATH T, Macosko EZ
    Insights into Neurodegeneration in Parkinson's Disease from Single-Cell and Spatial Genomics.
    Mov Disord. 2023 Mar 7. doi: 10.1002/mds.29374.
    >> Share

  199. DORSEY ER, Ray A
    Paraquat, Parkinson's Disease, and Agnotology.
    Mov Disord. 2023 Mar 6. doi: 10.1002/mds.29371.
    >> Share

  200. BLAUWENDRAAT C, Tayebi N, Woo EG, Lopez G, et al
    Polygenic Parkinson's Disease Genetic Risk Score as Risk Modifier of Parkinsonism in Gaucher Disease.
    Mov Disord. 2023 Mar 3. doi: 10.1002/mds.29342.
    >> Share

  201. MARSILI L, Duque KR, Gregor N, Abdelghany E, et al
    Bradykinesia in Neurodegenerative Disorders: A Blinded Video Analysis of Pathology-Proven Cases.
    Mov Disord. 2023;38:496-501.
    >> Share

  202. JENSEN PH, Schlossmacher MG, Stefanis L
    Who Ever Said It Would Be Easy? Reflecting on Two Clinical Trials Targeting alpha-Synuclein.
    Mov Disord. 2023;38:378-384.
    >> Share

  203. VIRAMETEEKUL S, Revesz T, Jaunmuktane Z, Warner TT, et al
    Pathological Validation of the MDS Criteria for the Diagnosis of Multiple System Atrophy.
    Mov Disord. 2023;38:444-452.
    >> Share

  204. WANG EW, Brown GL, Lewis MM, Jellen LC, et al
    Susceptibility Magnetic Resonance Imaging Correlates with Glial Density and Tau in the Substantia Nigra Pars Compacta.
    Mov Disord. 2023;38:464-473.
    >> Share

  205. TAN C, Nawaz H, Lageman SK, Cloud LJ, et al
    Cholinergic Nucleus 4 Degeneration and Cognitive Impairment in Isolated Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2023;38:474-479.
    >> Share

  206. WIEST C, Morgante F, Torrecillos F, Pogosyan A, et al
    Subthalamic Nucleus Stimulation-Induced Local Field Potential Changes in Dystonia.
    Mov Disord. 2023;38:423-434.
    >> Share

  207. ROSSI M, Hamed M, Rodriguez-Antiguedad J, Cornejo-Olivas M, et al
    Genotype-Phenotype Correlations for ATX-TBP (SCA17): MDSGene Systematic Review.
    Mov Disord. 2023;38:368-377.
    >> Share

    February 2023
  208. YACOUBIAN TA, Fang YD, Gerstenecker A, Amara A, et al
    Brain and Systemic Inflammation in De Novo Parkinson's Disease.
    Mov Disord. 2023 Feb 28. doi: 10.1002/mds.29363.
    >> Share

  209. EMMI A, Sandre M, Russo FP, Tombesi G, et al
    Duodenal alpha-Synuclein Pathology and Enteric Gliosis in Advanced Parkinson's Disease.
    Mov Disord. 2023 Feb 27. doi: 10.1002/mds.29358.
    >> Share

  210. SCIACCA G, Mostile G, Disilvestro I, Donzuso G, et al
    Long-Duration Response to Levodopa, Motor Learning, and Neuroplasticity in Early Parkinson's Disease.
    Mov Disord. 2023 Feb 25. doi: 10.1002/mds.29344.
    >> Share

  211. JUNG JH, Na HK, Jeong SH, Chung SJ, et al
    Effects of Dihydropyridines on the Motor and Cognitive Outcomes of Patients with Parkinson's Disease.
    Mov Disord. 2023 Feb 24. doi: 10.1002/mds.29367.
    >> Share

  212. LANDELLE C, Dahlberg LS, Lungu O, Misic B, et al
    Altered Spinal Cord Functional Connectivity Associated with Parkinson's Disease Progression.
    Mov Disord. 2023 Feb 21. doi: 10.1002/mds.29354.
    >> Share

  213. MANCINI A, Stoops E, Demeyer L, Bellomo G, et al
    LRRK2 Quantification in Cerebrospinal Fluid of Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes.
    Mov Disord. 2023 Feb 18. doi: 10.1002/mds.29336.
    >> Share

  214. JENNINGS D, Huntwork-Rodriguez S, Vissers MFJM, Daryani VM, et al
    LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease.
    Mov Disord. 2023 Feb 18. doi: 10.1002/mds.29297.
    >> Share

  215. SU D, Gan Y, Zhang Z, Cui Y, et al
    Multimodal Imaging of Substantia Nigra in Parkinson's Disease with Levodopa-Induced Dyskinesia.
    Mov Disord. 2023 Feb 17. doi: 10.1002/mds.29320.
    >> Share

  216. SUGIER PE, Lucotte EA, Domenighetti C, Law MH, et al
    Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers.
    Mov Disord. 2023 Feb 14. doi: 10.1002/mds.29337.
    >> Share

  217. NGUYEN TTH, Fournier A, Courtois E, Artaud F, et al
    Statin Use and Incidence of Parkinson's Disease in Women from the French E3N Cohort Study.
    Mov Disord. 2023 Feb 14. doi: 10.1002/mds.29349.
    >> Share

  218. AZIZ NA, Wullner U
    Genetic Variants in Sulfonylurea Targets Affect Parkinson's Disease Risk: A Two-Sample Mendelian Randomization Study.
    Mov Disord. 2023 Feb 13. doi: 10.1002/mds.29341.
    >> Share

  219. CONCHA-MARAMBIO L, Weber S, Farris CM, Dakna M, et al
    Accurate Detection of alpha-Synuclein Seeds in Cerebrospinal Fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa) Cohort.
    Mov Disord. 2023 Feb 13. doi: 10.1002/mds.29329.
    >> Share

  220. BECKER-COHEN M, Zimran A, Arkadir D, Revel-Vilk S, et al
    Has Parkinson Disease Gone to the Dogs?
    Mov Disord. 2023;38:358.
    >> Share

  221. GAO CQ, Zhang XX, Wang MM, Guo JF, et al
    Reply to: Has Parkinson Disease Gone to the Dogs?
    Mov Disord. 2023;38:359.
    >> Share

  222. GOETZ CG, Choi D, Guo Y, Stebbins GT, et al
    It Is as It Was: MDS-UPDRS Part III Scores Cannot Be Combined with Other Parts to Give a Valid Sum.
    Mov Disord. 2023;38:342-347.
    >> Share

  223. GARRIDO A, Fairfoul G, Tolosa E, Marti MJ, et al
    Brain and Cerebrospinal Fluid alpha-Synuclein Real-Time Quaking-Induced Conversion Identifies Lewy Body Pathology in LRRK2-PD.
    Mov Disord. 2023;38:333-338.
    >> Share

  224. OLSEN AL, Clemens SG, Feany MB
    Nicotine-Mediated Rescue of alpha-Synuclein Toxicity Requires Synaptic Vesicle Glycoprotein 2 in Drosophila.
    Mov Disord. 2023;38:244-255.
    >> Share

    January 2023
  225. FELDMANN LK, Lofredi R, Al-Fatly B, Busch JL, et al
    Christmas-Related Reduction in Beta Activity in Parkinson's Disease.
    Mov Disord. 2023 Jan 31. doi: 10.1002/mds.29334.
    >> Share

  226. STREUBEL-GALLASCH L, Seibler P
    Neuron-Derived Misfolded alpha-Synuclein in Blood: A Potential Biomarker for Parkinson's Disease?
    Mov Disord. 2023 Jan 31. doi: 10.1002/mds.29331.
    >> Share

  227. BORSCHE M, Martens A, Hormann P, Bruckmann T, et al
    In Vivo Investigation of Glucose Metabolism in Idiopathic and PRKN-Related Parkinson's Disease.
    Mov Disord. 2023 Jan 30. doi: 10.1002/mds.29333.
    >> Share

  228. KIM J, Inbo H, Kim HS, Kim W, et al
    First Clinical Report on the Treatment of Parkinson's Disease with Fetal Midbrain Precursor Cells.
    Mov Disord. 2023 Jan 24. doi: 10.1002/mds.29316.
    >> Share

  229. VOLLSTEDT EJ, Schaake S, Lohmann K, Padmanabhan S, et al
    Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort.
    Mov Disord. 2023 Jan 24. doi: 10.1002/mds.29288.
    >> Share

  230. BOKTOR JC, Sharon G, Verhagen Metman LA, Hall DA, et al
    Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome.
    Mov Disord. 2023 Jan 24. doi: 10.1002/mds.29300.
    >> Share

  231. KAASINEN V, Luo S, Martinez-Martin P, Goetz CG, et al
    Cross-Cultural Differences in Patient Perceptions of Dyskinesia in Parkinson's Disease.
    Mov Disord. 2023 Jan 20. doi: 10.1002/mds.29335.
    >> Share

  232. WEILL C, Gallant A, Baker Erdman H, Abu Snineh M, et al
    The Genetic Etiology of Parkinson's Disease Does Not Robustly Affect Subthalamic Physiology.
    Mov Disord. 2023 Jan 9. doi: 10.1002/mds.29310.
    >> Share

  233. GUO Y, Goetz CG, Stebbins GT, Mestre TA, et al
    Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings.
    Mov Disord. 2023 Jan 9. doi: 10.1002/mds.29308.
    >> Share

  234. ABDELHAFEEZ M, Elsayed I
    In Situ Global Structural Proteome Analysis Identifies Potential Biomarkers for Parkinson's Disease.
    Mov Disord. 2023 Jan 9. doi: 10.1002/mds.29315.
    >> Share

  235. VIRAMETEEKUL S, Revesz T, Jaunmuktane Z, Warner TT, et al
    Clinical Diagnostic Accuracy of Parkinson's Disease: Where Do We Stand?
    Mov Disord. 2023 Jan 5. doi: 10.1002/mds.29317.
    >> Share

  236. PARLAR SC, Grenn FP, Kim JJ, Baluwendraat C, et al
    Classification of GBA1 Variants in Parkinson's Disease: The GBA1-PD Browser.
    Mov Disord. 2023 Jan 4. doi: 10.1002/mds.29314.
    >> Share

  237. NOBILEAU A, Gaurav R, Chougar L, Faucher A, et al
    Neuromelanin-Sensitive Magnetic Resonance Imaging Changes in the Locus Coeruleus/Subcoeruleus Complex in Patients with Typical and Atypical Parkinsonism.
    Mov Disord. 2023 Jan 2. doi: 10.1002/mds.29309.
    >> Share

  238. LLOYD K, Lawton M, Whone A
    Practically Defined Off-State Dyskinesia Following Repeated Intraputamenal Glial Cell Line-Derived Neurotrophic Factor Administration.
    Mov Disord. 2023;38:104-112.
    >> Share

  239. BRINK-KJAER A, Gupta N, Marin E, Zitser J, et al
    Ambulatory Detection of Isolated Rapid-Eye-Movement Sleep Behavior Disorder Combining Actigraphy and Questionnaire.
    Mov Disord. 2023;38:82-91.
    >> Share

  240. ZHANG D, Zhou L, Shi Y, Liu J, et al
    Increased Free Water in the Substantia Nigra in Asymptomatic LRRK2 G2019S Mutation Carriers.
    Mov Disord. 2023;38:138-142.
    >> Share

  241. MATTIOLI P, Orso B, Liguori C, Fama F, et al
    Derivation and Validation of a Phenoconversion-Related Pattern in Idiopathic Rapid Eye Movement Behavior Disorder.
    Mov Disord. 2023;38:57-67.
    >> Share

    December 2022
  242. CULLINANE PW, de Pablo Fernandez E, Konig A, Outeiro TF, et al
    Type 2 Diabetes and Parkinson's Disease: A Focused Review of Current Concepts.
    Mov Disord. 2022 Dec 26. doi: 10.1002/mds.29298.
    >> Share

  243. BAIK K, Kim HR, Park M, Lee Y, et al
    Effect of Amyloid on Cognitive Performance in Parkinson's Disease and Dementia with Lewy Bodies.
    Mov Disord. 2022 Dec 17. doi: 10.1002/mds.29295.
    >> Share

  244. PALERMO G, Ceravolo R
    Clues to Reshaping Anti-alpha-Synuclein Immunotherapy in Early Parkinson's Disease Patients.
    Mov Disord. 2022 Dec 15. doi: 10.1002/mds.29294.
    >> Share

  245. NILSSON J, Constantinescu J, Nellgard B, Jakobsson P, et al
    Cerebrospinal Fluid Biomarkers of Synaptic Dysfunction Are Altered in Parkinson's Disease and Related Disorders.
    Mov Disord. 2022 Dec 12. doi: 10.1002/mds.29287.
    >> Share

  246. PINTO S, Nebel A, Rau J, Espesser R, et al
    Results of a Randomized Clinical Trial of Speech after Early Neurostimulation in Parkinson's Disease.
    Mov Disord. 2022 Dec 3. doi: 10.1002/mds.29282.
    >> Share

  247. RUSSO MJ, MacLeod K, Lamoureux J, Lebovitz R, et al
    Aggregation-Seeding Forms of alpha-Synuclein Are Not Detected in Acute Coronavirus Disease 2019 Cerebrospinal Fluid.
    Mov Disord. 2022;37:2462-2463.
    >> Share

  248. LORENZO-BETANCOR O, Galosi L, Bonfili L, Eleuteri AM, et al
    Homozygous CADPS2 Mutations Cause Neurodegenerative Disease with Lewy Body-like Pathology in Parrots.
    Mov Disord. 2022;37:2345-2354.
    >> Share

    November 2022
  249. DARMANI G, Drummond NM, Ramezanpour H, Saha U, et al
    Long-Term Recording of Subthalamic Aperiodic Activities and Beta Bursts in Parkinson's Disease.
    Mov Disord. 2022 Nov 24. doi: 10.1002/mds.29276.
    >> Share

  250. TALEBI AH, Ypinga JHL, De Vries NM, Nonnekes J, et al
    Specialized Versus Generic Allied Health Therapy and the Risk of Parkinson's Disease Complications.
    Mov Disord. 2022 Nov 24. doi: 10.1002/mds.29274.
    >> Share

  251. TANG Y, Li L, Hu T, Jiao F, et al
    In Vivo (18) F-Florzolotau Tau Positron Emission Tomography Imaging in Parkinson's Disease Dementia.
    Mov Disord. 2022 Nov 11. doi: 10.1002/mds.29273.
    >> Share

  252. KRAINC T, Monje MHG, Kinsinger M, Bustos BI, et al
    Melanin and Neuromelanin: Linking Skin Pigmentation and Parkinson's Disease.
    Mov Disord. 2022 Nov 9. doi: 10.1002/mds.29260.
    >> Share

  253. LEDONNE A, Massaro Cenere M, Paldino E, D'Angelo V, et al
    Morpho-Functional Changes of Nigral Dopamine Neurons in an alpha-Synuclein Model of Parkinson's Disease.
    Mov Disord. 2022 Nov 9. doi: 10.1002/mds.29269.
    >> Share

  254. HOENIG MC, Dzialas V, Drzezga A, van Eimeren T, et al
    The Concept of Motor Reserve in Parkinson's Disease: New Wine in Old Bottles?
    Mov Disord. 2022 Nov 7. doi: 10.1002/mds.29266.
    >> Share

  255. TROCHE MS, Curtis JA, Sevitz JS, Dakin AE, et al
    Rehabilitating Cough Dysfunction in Parkinson's Disease: A Randomized Controlled Trial.
    Mov Disord. 2022 Nov 7. doi: 10.1002/mds.29268.
    >> Share

  256. PIZARRO GALLEGUILLOS BM, Mohamed W, Perinan MT
    The Glycoprotein GPNMB: A Secret Ingredient for Understanding Parkinson's Disease Etiology?
    Mov Disord. 2022 Nov 2. doi: 10.1002/mds.29264.
    >> Share

  257. BOHNEN NI, Kanel P, van Emde Boas M, Roytman S, et al
    Vestibular Sensory Conflict During Postural Control, Freezing of Gait, and Falls in Parkinson's Disease.
    Mov Disord. 2022;37:2257-2262.
    >> Share

  258. PERCETTI M, Monfrini E, Caporali L, Minardi R, et al
    Reply to: No Association between Rare TWNK Variants and Parkinson's Disease in European Cohorts.
    Mov Disord. 2022;37:2319-2320.
    >> Share

  259. SOTIRAKIS C, Conway N, Su Z, Villarroel M, et al
    Longitudinal Monitoring of Progressive Supranuclear Palsy using Body-Worn Movement Sensors.
    Mov Disord. 2022;37:2263-2271.
    >> Share

  260. LEYS F, Eschlbock S, Campese N, Mahlknecht P, et al
    Family History for Neurodegeneration in Multiple System Atrophy: Does it Indicate Susceptibility?
    Mov Disord. 2022;37:2310-2312.
    >> Share

    October 2022
  261. BARTL M, Dakna M, Schade S, Otte B, et al
    Blood Markers of Inflammation, Neurodegeneration, and Cardiovascular Risk in Early Parkinson's Disease.
    Mov Disord. 2022 Oct 20. doi: 10.1002/mds.29257.
    >> Share

  262. VIVACQUA G, Mason M, De Bartolo MI, Wegrzynowicz M, et al
    Salivary alpha-Synuclein RT-QuIC Correlates with Disease Severity in de novo Parkinson's Disease.
    Mov Disord. 2022 Oct 19. doi: 10.1002/mds.29246.
    >> Share

  263. HULZINGA F, Seuthe J, D'Cruz N, Ginis P, et al
    Split-Belt Treadmill Training to Improve Gait Adaptation in Parkinson's Disease.
    Mov Disord. 2022 Oct 14. doi: 10.1002/mds.29238.
    >> Share

  264. CLERET DE LANGAVANT L, Roze E, Petit A, Tressieres B, et al
    Annonaceae Consumption Worsens Disease Severity and Cognitive Deficits in Degenerative Parkinsonism.
    Mov Disord. 2022 Oct 10. doi: 10.1002/mds.29222.
    >> Share

  265. ZIMPRICH A
    LRRK2 PROTAC Degraders as a Potential Novel Targeting Strategy for Parkinson's Disease?
    Mov Disord. 2022 Oct 5. doi: 10.1002/mds.29243.
    >> Share

  266. KIM R, Kim H, Kim YK, Yoon EJ, et al
    Brain Metabolic Correlates of Dopaminergic Denervation in Prodromal and Early Parkinson's Disease.
    Mov Disord. 2022;37:2099-2109.
    >> Share

  267. SAWAMURA M, Onoe H, Tsukada H, Isa K, et al
    Lewy Body Disease Primate Model with alpha-Synuclein Propagation from the Olfactory Bulb.
    Mov Disord. 2022;37:2033-2044.
    >> Share

  268. SOTO M, Iranzo A, Lahoz S, Fernandez M, et al
    Serum MicroRNAs Predict Isolated Rapid Eye Movement Sleep Behavior Disorder and Lewy Body Diseases.
    Mov Disord. 2022;37:2086-2098.
    >> Share

    September 2022
  269. DANG X, Zhang Z, Luo XJ
    Mendelian Randomization Study Using Dopaminergic Neuron-Specific eQTL Nominates Potential Causal Genes for Parkinson's Disease.
    Mov Disord. 2022 Sep 29. doi: 10.1002/mds.29239.
    >> Share

  270. PAULY C, Glaab E, Hansen M, Martin-Gallausiaux C, et al
    Disease Progression, Resilience, and Inflammation Markers During the Coronavirus Disease 2019 Pandemic in Parkinson's Disease.
    Mov Disord. 2022 Sep 23. doi: 10.1002/mds.29212.
    >> Share

  271. WILHELM E, Quoilin C, Derosiere G, Paco S, et al
    Corticospinal Suppression Underlying Intact Movement Preparation Fades in Parkinson's Disease.
    Mov Disord. 2022 Sep 19. doi: 10.1002/mds.29214.
    >> Share

  272. CHOU KL, Dayalu P, Koeppe RA, Gilman S, et al
    Serotonin Transporter Imaging in Multiple System Atrophy and Parkinson's Disease.
    Mov Disord. 2022 Sep 14. doi: 10.1002/mds.29220.
    >> Share

  273. MILLS KA, Pontone GM
    The Dawn of Precision Medicine for Deep Brain Stimulation in Parkinson's Disease?
    Mov Disord. 2022 Sep 14. doi: 10.1002/mds.29224.
    >> Share

  274. MENG Y, Pople CB, Huang Y, Jones RM, et al
    Putaminal Recombinant Glucocerebrosidase Delivery with Magnetic Resonance-Guided Focused Ultrasound in Parkinson's Disease: A Phase I Study.
    Mov Disord. 2022 Sep 11. doi: 10.1002/mds.29190.
    >> Share

  275. LANSBURY P
    The Sphingolipids Clearly Play a Role in Parkinson's Disease, but Nature Has Made it Complicated.
    Mov Disord. 2022 Sep 10. doi: 10.1002/mds.29204.
    >> Share

  276. LUO J, Wu H, Li J, Xian W, et al
    Joint Modeling Study Identifies Blood-Based Transcripts Link to Cognitive Decline in Parkinson's Disease.
    Mov Disord. 2022 Sep 10. doi: 10.1002/mds.29213.
    >> Share

  277. ZHANG X, Xu J, Liu Y, Chen S, et al
    Diet Quality is Associated with Prodromal Parkinson's Disease Features in Chinese Adults.
    Mov Disord. 2022 Sep 7. doi: 10.1002/mds.29208.
    >> Share

  278. SENKEVICH K, Gan-Or Z
    No Association Between Rare TWNK Variants and Parkinson's Disease in European Cohorts.
    Mov Disord. 2022 Sep 4. doi: 10.1002/mds.29216.
    >> Share

  279. SEIFAR F, Dinasarapu AR, Jinnah HA
    Uric Acid in Parkinson's Disease: What Is the Connection?
    Mov Disord. 2022 Sep 3. doi: 10.1002/mds.29209.
    >> Share

  280. HARIZ M, Bronstein JM, Cosgrove GR, de Bie RMA, et al
    European Academy of Neurology/Movement Disorder Society-European Section Guidelines on Pallidotomy for Parkinson's Disease: Let's Be Accurate.
    Mov Disord. 2022 Sep 1. doi: 10.1002/mds.29210.
    >> Share

    August 2022
  281. FERREIRA JJ, Poewe W, Rascol O, Stocchi F, et al
    Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease.
    Mov Disord. 2022 Aug 31. doi: 10.1002/mds.29193.
    >> Share

  282. COURTOIS E, Nguyen TTH, Fournier A, Carcaillon-Bentata L, et al
    Identifying Protective Drugs for Parkinson's Disease in Health-Care Databases Using Machine Learning.
    Mov Disord. 2022 Aug 29. doi: 10.1002/mds.29205.
    >> Share

  283. LI D, Mastaglia FL, Yau WY, Chen S, et al
    Targeted Molecular Therapeutics for Parkinson's Disease: A Role for Antisense Oligonucleotides?
    Mov Disord. 2022 Aug 29. doi: 10.1002/mds.29201.
    >> Share

  284. GOLFRE ANDREASI N, Cilia R, Romito LM, Bonvegna S, et al
    Magnetic Resonance-Guided Focused Ultrasound Thalamotomy May Spare Dopaminergic Therapy in Early-Stage Tremor-Dominant Parkinson's Disease: A Pilot Study.
    Mov Disord. 2022 Aug 29. doi: 10.1002/mds.29200.
    >> Share

  285. ORTEGA RA, Bressman SB, Raymond D, Ozelius LJ, et al
    Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism.
    Mov Disord. 2022 Aug 27. doi: 10.1002/mds.29197.
    >> Share

  286. GAO CQ, Wang SN, Wang MM, Li JJ, et al
    Sensitivity of Sniffer Dogs for a Diagnosis of Parkinson's Disease: A Diagnostic Accuracy Study.
    Mov Disord. 2022 Aug 25. doi: 10.1002/mds.29180.
    >> Share

  287. RUS T, Schindlbeck KA, Tang CC, Vo A, et al
    Stereotyped Relationship Between Motor and Cognitive Metabolic Networks in Parkinson's Disease.
    Mov Disord. 2022 Aug 23. doi: 10.1002/mds.29188.
    >> Share

  288. SIMMERING JE, Welsh MJ, Schultz J, Narayanan NS, et al
    Use of Glycolysis-Enhancing Drugs and Risk of Parkinson's Disease.
    Mov Disord. 2022 Aug 22. doi: 10.1002/mds.29184.
    >> Share

  289. STEFANO DP, Franciotti R, Chiacchiaretta P, Ferretti A, et al
    Altered Medial Prefrontal Connectivity in Parkinson's Disease Patients with Somatic Symptoms.
    Mov Disord. 2022 Aug 22. doi: 10.1002/mds.29187.
    >> Share

  290. YUAN X, Yang Y, Liu C, Tian Y, et al
    Fine Particulate Matter Triggers alpha-Synuclein Fibrillization and Parkinson-like Neurodegeneration.
    Mov Disord. 2022 Aug 22. doi: 10.1002/mds.29181.
    >> Share

  291. REYES CJ, Asano K, Todd PK, Klein C, et al
    Repeat-Associated Non-AUG Translation of AGAGGG Repeats that Cause X-Linked Dystonia-Parkinsonism.
    Mov Disord. 2022 Aug 16. doi: 10.1002/mds.29183.
    >> Share

  292. SAFARPOUR D, Brumbach BH, Arena M, Quinn J, et al
    Gastrointestinal Motility and Response to Levodopa in Parkinson's Disease: A Proof-of-Concept Study.
    Mov Disord. 2022 Aug 15. doi: 10.1002/mds.29176.
    >> Share

  293. SMIT JW, Basile P, Prato MK, Detalle L, et al
    Phase 1/1b Studies of UCB0599, an Oral Inhibitor of alpha-Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease.
    Mov Disord. 2022 Aug 12. doi: 10.1002/mds.29170.
    >> Share

  294. BANWINKLER M, Dzialas V, Hoenig MC, van Eimeren T, et al
    Gray Matter Volume Loss in Proposed Brain-First and Body-First Parkinson's Disease Subtypes.
    Mov Disord. 2022 Aug 9. doi: 10.1002/mds.29172.
    >> Share

  295. MCKEE KE, Gilbert RM, Spigle WA, Tilley BC, et al
    Inclusion of Non-English-Speaking Participants in Studies of Parkinson's Disease: A Call to Action.
    Mov Disord. 2022 Aug 5. doi: 10.1002/mds.29179.
    >> Share

  296. TANG X, Gonzalez-Latapi P, Marras C, Visanji NP, et al
    Epigenetic Clock Acceleration Is Linked to Age at Onset of Parkinson's Disease.
    Mov Disord. 2022 Aug 3. doi: 10.1002/mds.29157.
    >> Share

  297. SURFACE M, Balwani M, Waters C, Haimovich A, et al
    Reply to: "Could Blood Hexosylsphingosine Be a Marker for Parkinson's Disease Linked with GBA1 Mutations"?
    Mov Disord. 2022;37:1782.
    >> Share

  298. GLEASON AM, Tayebi N, Lopez GJ, Sidransky E, et al
    Reply to: "Overlapping Ranges in Levels Indicate That Hexosylsphingosine Is Not a Clinically Relevant Biomarker for GBA1-Associated Parkinson's Disease".
    Mov Disord. 2022;37:1781-1782.
    >> Share

  299. LI C, Lin J, Gu X, Hou Y, et al
    Mutation Screening of TFG in alpha-Synucleinopathy and Amyotrophic Lateral Sclerosis.
    Mov Disord. 2022;37:1756-1761.
    >> Share

  300. PAZ RM, Stahl AM, Rela L, Murer MG, et al
    D1/D5 Inverse Agonists Restore Striatal Cholinergic Interneuron Physiology in Dyskinetic Mice.
    Mov Disord. 2022;37:1693-1706.
    >> Share

    July 2022
  301. DAIDA K, Shimonaka S, Shiba-Fukushima K, Ogata J, et al
    alpha-Synuclein V15A Variant in Familial Parkinson's Disease Exhibits a Weaker Lipid-Binding Property.
    Mov Disord. 2022 Jul 27. doi: 10.1002/mds.29162.
    >> Share

  302. TE VRUCHTE D, Sturchio A, Priestman DA, Tsitsi P, et al
    Glycosphingolipid Changes in Plasma in Parkinson's Disease Independent of Glucosylceramide Levels.
    Mov Disord. 2022 Jul 25. doi: 10.1002/mds.29163.
    >> Share

  303. SCHUMACHER-SCHUH AF, Bieger A, Okunoye O, Mok KY, et al
    Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions.
    Mov Disord. 2022 Jul 22. doi: 10.1002/mds.29126.
    >> Share

  304. RAJAN R, Garg K, Srivastava AK, Singh M, et al
    Device-Assisted and Neuromodulatory Therapies for Parkinson's Disease: A Network Meta-Analysis.
    Mov Disord. 2022 Jul 22. doi: 10.1002/mds.29160.
    >> Share

  305. BILLINGSLEY KJ, Alvarez Jerez P, Grenn FP, Bandres-Ciga S, et al
    Profiling the NOTCH2NLC GGC Repeat Expansion in Parkinson's Disease in the European Population.
    Mov Disord. 2022 Jul 22. doi: 10.1002/mds.29155.
    >> Share

  306. LIU FT, Li XY, Lu JY, Wu P, et al
    (18) F-Florzolotau Tau Positron Emission Tomography Imaging in Patients with Multiple System Atrophy-Parkinsonian Subtype.
    Mov Disord. 2022 Jul 21. doi: 10.1002/mds.29159.
    >> Share

  307. MARANO M, Anzini G, Musumeci G, Magliozzi A, et al
    Transcutaneous Auricular Vagus Stimulation Improves Gait and Reaction Time in Parkinson's Disease.
    Mov Disord. 2022 Jul 21. doi: 10.1002/mds.29166.
    >> Share

  308. ILIEVA NM, De Miranda BR
    Rest and Digest-The Basal Role of Autophagy in Neurons and Its Relevance to Parkinson's Disease.
    Mov Disord. 2022 Jul 20. doi: 10.1002/mds.29165.
    >> Share

  309. LU J, Ge J, Chen K, Sun Y, et al
    Consistent Abnormalities in Metabolic Patterns of Lewy Body Dementias.
    Mov Disord. 2022 Jul 20. doi: 10.1002/mds.29138.
    >> Share

  310. PEREZ-OLIVEIRA S, Alvarez I, Rosas I, Menendez-Gonzalez M, et al
    Intermediate and Expanded HTT Alleles and the Risk for alpha-Synucleinopathies.
    Mov Disord. 2022 Jul 19. doi: 10.1002/mds.29153.
    >> Share

  311. LUO S, Zou H, Stebbins GT, Schwarzschild MA, et al
    Dissecting the Domains of Parkinson's Disease: Insights from Longitudinal Item Response Theory Modeling.
    Mov Disord. 2022 Jul 16. doi: 10.1002/mds.29154.
    >> Share

  312. DELVA A, Van Laere K, Vandenberghe W
    Longitudinal Positron Emission Tomography Imaging of Presynaptic Terminals in Early Parkinson's Disease.
    Mov Disord. 2022 Jul 12. doi: 10.1002/mds.29148.
    >> Share

  313. DOMENIGHETTI C, Douillard V, Sugier PE, Sreelatha AAK, et al
    The Interaction between HLA-DRB1 and Smoking in Parkinson's Disease Revisited.
    Mov Disord. 2022 Jul 10. doi: 10.1002/mds.29133.
    >> Share

  314. SUBERT M, Simek M, Novotny M, Tykalova T, et al
    Linguistic Abnormalities in Isolated Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2022 Jul 7. doi: 10.1002/mds.29140.
    >> Share

  315. PERCETTI M, Franco G, Monfrini E, Caporali L, et al
    TWNK in Parkinson's Disease: A Movement Disorder and Mitochondrial Disease Center Perspective Study.
    Mov Disord. 2022 Jul 6. doi: 10.1002/mds.29139.
    >> Share

  316. KOPYTOVA AE, Usenko TS, Baydakova GV, Nikolaev MA, et al
    Could Blood Hexosylsphingosine Be a Marker for Parkinson's Disease Linked with GBA1 Mutations?
    Mov Disord. 2022 Jul 6. doi: 10.1002/mds.29132.
    >> Share

  317. DEUSCHL G, Antonini A, Costa J, Smilowska K, et al
    European Academy of Neurology/Movement Disorder Society-European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies.
    Mov Disord. 2022 Jul 6. doi: 10.1002/mds.29066.
    >> Share

  318. VIJIARATNAM N, Lawton M, Real R, Heslegrave AJ, et al
    Diabetes and Neuroaxonal Damage in Parkinson's Disease.
    Mov Disord. 2022;37:1568-1569.
    >> Share

  319. BUHMANN C, Potter-Nerger M, Schulz R, Gerloff C, et al
    Reply to: "Diabetes and Neuroaxonal Damage in Parkinson's Disease".
    Mov Disord. 2022;37:1569-1570.
    >> Share

  320. COCHEN DE COCK V, Dotov D, Damm L, Janaqi S, et al
    Reply to: "Is Gait Dysfunction Prominent Sign of Isolated Rapid Eye Movement Sleep Behavior Disorder?"
    Mov Disord. 2022;37:1576-1577.
    >> Share

  321. KLARENDIC M, Kojovic M
    Reply to: "Neither Friend Nor Foe: Beekeeping and Parkinson's Disease".
    Mov Disord. 2022;37:1575.
    >> Share

  322. NETUKOVA S, Rusz J, Ruzicka E, Krupicka R, et al
    Is Gait Dysfunction a Prominent Sign of Isolated Rapid Eye Movement Sleep Behavior Disorder?
    Mov Disord. 2022;37:1575-1576.
    >> Share

  323. WASNER K, Smajic S, Ghelfi J, Delcambre S, et al
    Parkin Deficiency Impairs Mitochondrial DNA Dynamics and Propagates Inflammation.
    Mov Disord. 2022;37:1405-1415.
    >> Share

  324. YU HJ, Thijssen E, van Brummelen E, van der Plas JL, et al
    A Randomized First-in-Human Study With UB-312, a UBITh(R) alpha-Synuclein Peptide Vaccine.
    Mov Disord. 2022;37:1416-1424.
    >> Share

  325. TAYLOR NL, Wainstein G, Quek D, Lewis SJG, et al
    The Contribution of Noradrenergic Activity to Anxiety-Induced Freezing of Gait.
    Mov Disord. 2022;37:1432-1443.
    >> Share

    June 2022
  326. LABANDEIRA-GARCIA JL, Parga JA
    Nigral Neurons Degenerating in Parkinson's Disease Express the Angiotensin Receptor Type 1 Gene.
    Mov Disord. 2022 Jun 29. doi: 10.1002/mds.29137.
    >> Share

  327. PINEDA-PARDO JA, Gasca-Salas C, Fernandez-Rodriguez B, Rodriguez-Rojas R, et al
    Striatal Blood-Brain Barrier Opening in Parkinson's Disease Dementia: A Pilot Exploratory Study.
    Mov Disord. 2022 Jun 28. doi: 10.1002/mds.29134.
    >> Share

  328. POHL EDR, Upadhyay N, Kobeleva X, Purrer V, et al
    Coherent Structural and Functional Network Changes after Thalamic Lesions in Essential Tremor.
    Mov Disord. 2022 Jun 23. doi: 10.1002/mds.29130.
    >> Share

  329. WANG P, Pan J, Luo Q, Chen J, et al
    A 10-Year Community-Based Study of Leucine-Rich Repeat Kinase 2 G2385R Carriers' Conversion to Parkinson's Disease.
    Mov Disord. 2022 Jun 22. doi: 10.1002/mds.29127.
    >> Share

  330. STRAKA I, Svantnerova J, Minar M, Stankova S, et al
    Neurodevelopmental Gene-Related Dystonia-Parkinsonism with Onset in Adults: A Case with NAA15 Variant.
    Mov Disord. 2022 Jun 22. doi: 10.1002/mds.29125.
    >> Share

  331. XIE A, Ensink E, Li P, Gordevicius J, et al
    Bacterial Butyrate in Parkinson's Disease Is Linked to Epigenetic Changes and Depressive Symptoms.
    Mov Disord. 2022 Jun 20. doi: 10.1002/mds.29128.
    >> Share

  332. LUO S, Goetz CG, Choi D, Aggarwal S, et al
    Resolving Missing Data from the Movement Disorder Society Unified Parkinson's Disease Rating Scale: Implications for Telemedicine.
    Mov Disord. 2022 Jun 18. doi: 10.1002/mds.29129.
    >> Share

  333. COKU I, Mutez E, Eddarkaoui S, Carrier S, et al
    Functional Analyses of Two Novel LRRK2 Pathogenic Variants in Familial Parkinson's Disease.
    Mov Disord. 2022 Jun 16. doi: 10.1002/mds.29124.
    >> Share

  334. OLSON JW, Nakhmani A, Irwin ZT, Edwards LJ, et al
    Cortical and Subthalamic Nucleus Spectral Changes During Limb Movements in Parkinson's Disease Patients with and Without Dystonia.
    Mov Disord. 2022 Jun 14. doi: 10.1002/mds.29057.
    >> Share

  335. ATHAUDA D, Evans J, Wernick A, Virdi G, et al
    The Impact of Type 2 Diabetes in Parkinson's Disease.
    Mov Disord. 2022 Jun 14. doi: 10.1002/mds.29122.
    >> Share

  336. AJALIN RM, Al-Abdulrasul H, Tuisku JM, Hirvonen JES, et al
    Cannabinoid Receptor Type 1 in Parkinson's Disease: A Positron Emission Tomography Study with [(18) F]FMPEP-d2.
    Mov Disord. 2022 Jun 8. doi: 10.1002/mds.29117.
    >> Share

  337. RINNE JO, Jucaite A, Cselenyi Z, Farde L, et al
    Glia Imaging Shows Clinical Utility in Differentiating Parkinson's Disease from Multiple System Atrophy.
    Mov Disord. 2022 Jun 6. doi: 10.1002/mds.29078.
    >> Share


  338. The PSG 32nd Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson Disease and Other Movement Disorders.
    Mov Disord. 2022;37 Suppl 1:S1-S36.
    >> Share

  339. SCHAEFFER E, Toedt I, Kohler S, Rogge A, et al
    Reply to: "Risk Disclosure in Prodromal Parkinson's Disease".
    Mov Disord. 2022;37:1327.
    >> Share

  340. MORRIS LA, O'Callaghan C, Le Heron C
    Disordered Decision Making: A Cognitive Framework for Apathy and Impulsivity in Huntington's Disease.
    Mov Disord. 2022;37:1149-1163.
    >> Share

    May 2022
  341. HOBSON DE, Del Bigio MR
    Beekeeper Parkinsonism.
    Mov Disord. 2022 May 31. doi: 10.1002/mds.29076.
    >> Share

  342. LI C, Hou Y, Ou R, Gu X, et al
    Genetic Determinants of Survival in Parkinson's Disease in the Asian Population.
    Mov Disord. 2022 May 26. doi: 10.1002/mds.29069.
    >> Share

  343. DU G, Wang E, Sica C, Chen H, et al
    Dynamics of Nigral Iron Accumulation in Parkinson's Disease: From Diagnosis to Late Stage.
    Mov Disord. 2022 May 25. doi: 10.1002/mds.29062.
    >> Share

  344. YANG X, Ai P, He X, Mo C, et al
    Parkinson's Disease Is Associated with Impaired Gut-Blood Barrier for Short-Chain Fatty Acids.
    Mov Disord. 2022 May 24. doi: 10.1002/mds.29063.
    >> Share

  345. KIM R, Kim HJ, Shin JH, Lee CY, et al
    Serum Inflammatory Markers and Progression of Nonmotor Symptoms in Early Parkinson's Disease.
    Mov Disord. 2022 May 21. doi: 10.1002/mds.29056.
    >> Share

  346. SMEYNE RJ, Eells JB, Chatterjee D, Byrne M, et al
    COVID-19 infection enhances susceptibility to oxidative-stress induced parkinsonism.
    Mov Disord. 2022 May 17. doi: 10.1002/mds.29116.
    >> Share

  347. YE R, O'Callaghan C, Rua C, Hezemans FH, et al
    Locus Coeruleus Integrity from 7 T MRI Relates to Apathy and Cognition in Parkinsonian Disorders.
    Mov Disord. 2022 May 16. doi: 10.1002/mds.29072.
    >> Share

  348. MAHLKNECHT P, Foltynie T, Limousin P, Poewe W, et al
    How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?
    Mov Disord. 2022 May 12. doi: 10.1002/mds.29052.
    >> Share

  349. YAMASHITA R, Beck G, Yonenobu Y, Inoue K, et al
    TDP-43 Proteinopathy Presenting with Typical Symptoms of Parkinson's Disease.
    Mov Disord. 2022 May 9. doi: 10.1002/mds.29048.
    >> Share

  350. SOSSI V, Patterson JR, McCormick S, Kemp CJ, et al
    Dopaminergic Positron Emission Tomography Imaging in the Alpha-Synuclein Preformed Fibril Model Reveals Similarities to Early Parkinson's Disease.
    Mov Disord. 2022 May 7. doi: 10.1002/mds.29051.
    >> Share

  351. WANG S, Unnithan S, Bryant N, Chang A, et al
    Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease.
    Mov Disord. 2022 May 6. doi: 10.1002/mds.29043.
    >> Share

  352. PAN Y, Xue J, Chen J, Zhang X, et al
    Assessment of GGC Repeat Expansion in GIPC1 in Patients with Parkinson's Disease.
    Mov Disord. 2022 May 6. doi: 10.1002/mds.29041.
    >> Share

  353. FILIPPI M, Balestrino R, Basaia S, Agosta F, et al
    Neuroimaging in Glucocerebrosidase-Associated Parkinsonism: A Systematic Review.
    Mov Disord. 2022 May 6. doi: 10.1002/mds.29047.
    >> Share

  354. ZHOU X, Liu Z, Zhou X, Xiang Y, et al
    The Chinese Parkinson's Disease Registry (CPDR): Study Design and Baseline Patient Characteristics.
    Mov Disord. 2022 May 3. doi: 10.1002/mds.29037.
    >> Share

  355. STEINHARDT J, Hanssen H, Heldmann M, Sprenger A, et al
    Prodromal X-Linked Dystonia-Parkinsonism is Characterized by a Subclinical Motor Phenotype.
    Mov Disord. 2022 May 2. doi: 10.1002/mds.29033.
    >> Share

  356. MACIAS-GARCIA D, Perinan MT, Munoz-Delgado L, Jesus S, et al
    Reply to: "Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations".
    Mov Disord. 2022;37:1119-1120.
    >> Share

  357. GRISANTI S, Ferri L, Cavallieri F, Fioravanti V, et al
    Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations.
    Mov Disord. 2022;37:1117-1118.
    >> Share

  358. LAANSMA MA, Bright JK, Jahanshad N, Thompson PM, et al
    Reply to: "Parkinson's Disease, Premature Mortality, and Amygdala".
    Mov Disord. 2022;37:1111-1112.
    >> Share

  359. RAO SC, Pattipati S, Salim A, Gutierrez N, et al
    Promoting Gender Inclusivity: A Questionnaire for Women's Health Factors in Parkinson's Disease.
    Mov Disord. 2022;37:1112-1113.
    >> Share

  360. SCORZA FA, de Almeida AG, Scorza CA, Finsterer J, et al
    Parkinson's Disease, Premature Mortality, and Amygdala.
    Mov Disord. 2022;37:1110-1111.
    >> Share

  361. DARWEESH SKL, Vermeulen R, Bloem BR, Peters S, et al
    Exposure to Pesticides Predicts Prodromal Feature of Parkinson's Disease: Public Health Implications.
    Mov Disord. 2022;37:883-885.
    >> Share

  362. SUBRAMANIAN I, Mathur S, Oosterbaan A, Flanagan R, et al
    Reply to: "Promoting Gender Inclusivity: A questionnaire for Women's Health Factors in Parkinson's Disease".
    Mov Disord. 2022;37:1113.
    >> Share

  363. FOFFANI G
    An Exponential Rather Than Multistep Model of Parkinson's Disease Pathogenesis.
    Mov Disord. 2022;37:1105-1106.
    >> Share

  364. ALZGHOOL OM, van Dongen G, van de Giessen E, Schoonmade L, et al
    alpha-Synuclein Radiotracer Development and In Vivo Imaging: Recent Advancements and New Perspectives.
    Mov Disord. 2022;37:936-948.
    >> Share

  365. GANAPATHY S R, Levova K, Kotackova L, Trnka J, et al
    Increased Transferrin Sialylation Predicts Phenoconversion in Isolated REM Sleep Behavior Disorder.
    Mov Disord. 2022;37:983-992.
    >> Share

  366. TODISCO M, Cosentino G, Scardina S, Fresia M, et al
    Diagnostic and Prognostic Value of External Anal Sphincter EMG Patterns in Multiple System Atrophy.
    Mov Disord. 2022;37:1069-1074.
    >> Share

  367. GAURAV R, Pyatigorskaya N, Biondetti E, Valabregue R, et al
    Deep Learning-Based Neuromelanin MRI Changes of Isolated REM Sleep Behavior Disorder.
    Mov Disord. 2022;37:1064-1069.
    >> Share

    April 2022
  368. BANDRES-CIGA S
    Black and African American Connections to Parkinson's Disease Study: Addressing Missing Diversity in Parkinson's Disease Genetics.
    Mov Disord. 2022 Apr 30. doi: 10.1002/mds.29042.
    >> Share

  369. TANIMURA A, Shen W, Wokosin D, Surmeier DJ, et al
    Pathway-Specific Remodeling of Thalamostriatal Synapses in a Mouse Model of Parkinson's Disease.
    Mov Disord. 2022 Apr 29. doi: 10.1002/mds.29030.
    >> Share

  370. KARAGIANIS JL
    Re: Risk Disclosure in Prodromal Parkinson's Disease.
    Mov Disord. 2022 Apr 28. doi: 10.1002/mds.29038.
    >> Share

  371. LANGE LM, Gonzalez-Latapi P, Rajalingam R, Tijssen MAJ, et al
    Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force - An Update.
    Mov Disord. 2022 Apr 28. doi: 10.1002/mds.28982.
    >> Share

  372. KOLMANCIC K, Zupancic NK, Trost M, Flisar D, et al
    Continuous Dopaminergic Stimulation Improves Cortical Maladaptive Changes in Advanced Parkinson's Disease.
    Mov Disord. 2022 Apr 18. doi: 10.1002/mds.29028.
    >> Share

  373. YASSINE S, Gschwandtner U, Auffret M, Achard S, et al
    Functional Brain Dysconnectivity in Parkinson's Disease: A 5-Year Longitudinal Study.
    Mov Disord. 2022 Apr 14. doi: 10.1002/mds.29026.
    >> Share

  374. RAMIREZ J, Berberian SA, Breen DP, Gao F, et al
    Small and Large Magnetic Resonance Imaging-Visible Perivascular Spaces in the Basal Ganglia of Parkinson's Disease Patients.
    Mov Disord. 2022 Apr 11. doi: 10.1002/mds.29010.
    >> Share

  375. QUATTRONE A, Bianco MG, Antonini A, Vaillancourt DE, et al
    Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy-Parkinsonism From Parkinson's Disease.
    Mov Disord. 2022 Apr 11. doi: 10.1002/mds.28992.
    >> Share

  376. UYAR M, Lezius S, Buhmann C, Potter-Nerger M, et al
    Diabetes, Glycated Hemoglobin (HbA1c), and Neuroaxonal Damage in Parkinson's Disease (MARK-PD Study).
    Mov Disord. 2022 Apr 6. doi: 10.1002/mds.29009.
    >> Share

  377. BARBA L, Paolini Paoletti F, Bellomo G, Gaetani L, et al
    Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers.
    Mov Disord. 2022;37:669-683.
    >> Share

  378. THIJSSEN E, den Heijer J, Puibert D, Moss L, et al
    A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During Morning Off of AZ-009.
    Mov Disord. 2022;37:790-798.
    >> Share

  379. GRIJALVA RM, Pham NTT, Huang Q, Martin PR, et al
    Brainstem Biomarkers of Clinical Variant and Pathology in Progressive Supranuclear Palsy.
    Mov Disord. 2022;37:702-712.
    >> Share

    March 2022
  380. CHOUGAR L, Arsovic E, Gaurav R, Biondetti E, et al
    Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism.
    Mov Disord. 2022 Mar 29. doi: 10.1002/mds.28988.
    >> Share

  381. LE HERON C, MacAskill MR, Myall DJ
    Reply to: "An Exponential Rather Than Multistep Model of Parkinson's Disease Pathogenesis".
    Mov Disord. 2022 Mar 28. doi: 10.1002/mds.28989.
    >> Share

  382. XU Y, Feeney MP, Surface M, Novak D, et al
    Attitudes Toward Telehealth Services Among People Living With Parkinson's Disease: A Survey Study.
    Mov Disord. 2022 Mar 26. doi: 10.1002/mds.28990.
    >> Share

  383. SIGURDSSON HP, Yarnall AJ, Galna B, Lord S, et al
    Gait-Related Metabolic Covariance Networks at Rest in Parkinson's Disease.
    Mov Disord. 2022 Mar 14. doi: 10.1002/mds.28977.
    >> Share

  384. NAKANO Y, Hirano S, Kojima K, Li H, et al
    Dopaminergic Correlates of Regional Cerebral Blood Flow in Parkinsonian Disorders.
    Mov Disord. 2022 Mar 14. doi: 10.1002/mds.28981.
    >> Share

  385. LUAN M, Sun Y, Chen J, Jiang Y, et al
    Diagnostic Value of Salivary Real-Time Quaking-Induced Conversion in Parkinson's Disease and Multiple System Atrophy.
    Mov Disord. 2022 Mar 12. doi: 10.1002/mds.28976.
    >> Share

  386. MURTOMAKI K, Mertsalmi T, Jaakkola E, Makinen E, et al
    Gastrointestinal Symptoms and Dopamine Transporter Asymmetry in Early Parkinson's Disease.
    Mov Disord. 2022 Mar 11. doi: 10.1002/mds.28986.
    >> Share

  387. STRANIERO L, Rimoldi V, Monfrini E, Bonvegna S, et al
    Role of Lysosomal Gene Variants in Modulating GBA-Associated Parkinson's Disease Risk.
    Mov Disord. 2022 Mar 9. doi: 10.1002/mds.28987.
    >> Share

  388. KUSTERS CDJ, Paul KC, Duarte Folle A, Keener AM, et al
    Erratum to "Increased Menopausal Age Reduces the Risk of Parkinson's Disease: A Mendelian Approach".
    Mov Disord. 2022 Mar 4. doi: 10.1002/mds.28974.
    >> Share

  389. PRANGE S, Metereau E, Maillet A, Klinger H, et al
    Limbic Serotonergic Plasticity Contributes to the Compensation of Apathy in Early Parkinson's Disease.
    Mov Disord. 2022 Mar 3. doi: 10.1002/mds.28971.
    >> Share

  390. OLSZEWSKA DA, Lang AE
    The Role of Insular Cortex in Gut-Inflammation Memory: What Does It Mean for Parkinson's Disease?
    Mov Disord. 2022 Mar 1. doi: 10.1002/mds.28975.
    >> Share

  391. LIN CH, Lin HY, Ho EP, Ke YC, et al
    Reply to: Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice through Activating TNF-alpha Pathway.
    Mov Disord. 2022;37:665-666.
    >> Share

  392. SAMBIN S, Menon PJ, Ihle J, Mariani LL, et al
    Down-Regulation of Dopamine Transporter in Early Premotor Phases.
    Mov Disord. 2022;37:663-664.
    >> Share

  393. LINARD M, Ravier A, Mougue L, Grgurina I, et al
    Infectious Agents as Potential Drivers of alpha-Synucleinopathies.
    Mov Disord. 2022;37:464-477.
    >> Share

  394. ROEDIGER J, Dembek TA, Wenzel G, Butenko K, et al
    StimFit-A Data-Driven Algorithm for Automated Deep Brain Stimulation Programming.
    Mov Disord. 2022;37:574-584.
    >> Share

  395. JANZEN A, Kogan RV, Meles SK, Sittig E, et al
    Rapid Eye Movement Sleep Behavior Disorder: Abnormal Cardiac Image and Progressive Abnormal Metabolic Brain Pattern.
    Mov Disord. 2022;37:624-629.
    >> Share

    February 2022
  396. RAO SC, Sanyaolu AO
    Breaking Barriers: Modeling the Blood-Brain Barrier in Parkinson's Disease Using a Human-Brain-Chip.
    Mov Disord. 2022 Feb 28. doi: 10.1002/mds.28968.
    >> Share

  397. RASCOL O, Medori R, Baayen C, Such P, et al
    A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease.
    Mov Disord. 2022 Feb 26. doi: 10.1002/mds.28970.
    >> Share

  398. KHALIL H, Aldaajani ZF, Aldughmi M, Al-Sharman A, et al
    Validation of the Arabic Version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.
    Mov Disord. 2022 Feb 26. doi: 10.1002/mds.28905.
    >> Share

  399. CORNEJO-OLIVAS M, Wu L, Noyce A
    Disruption of Mitochondrial Complex I Induces Progressive Parkinsonism.
    Mov Disord. 2022 Feb 22. doi: 10.1002/mds.28961.
    >> Share

  400. XING Y, Sapuan AH, Martin-Bastida A, Naidu S, et al
    Neuromelanin-MRI to Quantify and Track Nigral Depigmentation in Parkinson's Disease: A Multicenter Longitudinal Study Using Template-Based Standardized Analysis.
    Mov Disord. 2022 Feb 15. doi: 10.1002/mds.28934.
    >> Share

  401. LIZARRAGA KJ, Gnanamanogaran B, Al-Ozzi TM, Cohn M, et al
    Lateralized Subthalamic Stimulation for Axial Dysfunction in Parkinson's Disease: A Randomized Trial.
    Mov Disord. 2022 Feb 13. doi: 10.1002/mds.28953.
    >> Share

  402. MAGRINELLI F, Rajapaksha I, Kobylecki C, Latorre A, et al
    Reply to: Juvenile PLA2G6-parkinsonism due to Indian 'Asian' p.R741Q mutation, and response to STN DBS.
    Mov Disord. 2022 Feb 13. doi: 10.1002/mds.28955.
    >> Share

  403. AYTON S, Hall S, Janelidze S, Kalinowski P, et al
    The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders.
    Mov Disord. 2022 Feb 8. doi: 10.1002/mds.28958.
    >> Share

  404. PRASUHN J, Gottlich M, Grosser SS, Reuther K, et al
    In Vivo Brain Sodium Disequilibrium in ATP1A3-Related Rapid-Onset Dystonia-Parkinsonism.
    Mov Disord. 2022 Feb 7. doi: 10.1002/mds.28954.
    >> Share

  405. MADELUNG CF, Meder D, Fuglsang SA, Marques MM, et al
    Locus Coeruleus Shows a Spatial Pattern of Structural Disintegration in Parkinson's Disease.
    Mov Disord. 2022 Feb 3. doi: 10.1002/mds.28945.
    >> Share

  406. RAVAT P, Shinde S, Shinde SR, Bangar S, et al
    Juvenile PLA2G6-Parkinsonism Due to Indian 'Asian' p.R741Q Mutation, and Response to STN DBS.
    Mov Disord. 2022 Feb 3. doi: 10.1002/mds.28950.
    >> Share

  407. SZWEDO AA, Dalen I, Pedersen KF, Camacho M, et al
    GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study.
    Mov Disord. 2022 Feb 2. doi: 10.1002/mds.28932.
    >> Share

  408. ORTEGA RA, Bodamer O, Peake RWA, Raymond D, et al
    Assessment of Glucocerebrosidase Enzyme Activity in Parkinson Disease Using Multiple Approaches.
    Mov Disord. 2022 Feb 1. doi: 10.1002/mds.28951.
    >> Share

  409. AAMODT WW, Chen-Plotkin AS
    Reply to: "Age-Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK-PD)".
    Mov Disord. 2022;37:436-437.
    >> Share

  410. TODT I, Al-Fatly B, Granert O, Kuhn AA, et al
    The Contribution of Subthalamic Nucleus Deep Brain Stimulation to the Improvement in Motor Functions and Quality of Life.
    Mov Disord. 2022;37:291-301.
    >> Share

  411. D'CRUZ N, Seuthe J, De Somer C, Hulzinga F, et al
    Dual Task Turning in Place: A Reliable, Valid, and Responsive Outcome Measure of Freezing of Gait.
    Mov Disord. 2022;37:269-278.
    >> Share

  412. ZIRRA A, Huxford B
    CD4(+) T Cells Contribute to Neurodegeneration in Lewy Body Dementia.
    Mov Disord. 2022;37:268.
    >> Share

    January 2022
  413. DERKINDEREN P, de Guilhem de Lataillade A, Neunlist M, Rolli-Derkinderen M, et al
    Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice through Activating TNF-alpha Pathway.
    Mov Disord. 2022 Jan 31. doi: 10.1002/mds.28948.
    >> Share

  414. SURFACE M, Balwani M, Waters C, Haimovich A, et al
    Reply to: No Evidence that Glucosylsphingosine Is a Biomarker for Parkinson Disease.
    Mov Disord. 2022 Jan 29. doi: 10.1002/mds.28936.
    >> Share

  415. LIU W, Yu Y
    Single-Trajectory Multiple Target for Parkinsonian Mobility and Cognition? An Inadvisable Idea.
    Mov Disord. 2022 Jan 28. doi: 10.1002/mds.28949.
    >> Share

  416. GLEASON A, Tayebi N, Lopez G, Sidransky E, et al
    No Evidence That Glucosylsphingosine Is a Biomarker for Parkinson's Disease: Statistical Differences Do Not Necessarily Indicate Biological Significance.
    Mov Disord. 2022 Jan 24. doi: 10.1002/mds.28935.
    >> Share

  417. OMER N, Giladi N, Gurevich T, Bar-Shira A, et al
    Glucocerebrosidase Activity Is Not Associated with Parkinson's Disease Risk or Severity.
    Mov Disord. 2022 Jan 22. doi: 10.1002/mds.28929.
    >> Share

  418. GARRIDO A, Santamaria E, Fernandez-Irigoyen J, Soto M, et al
    Differential Phospho-Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease.
    Mov Disord. 2022 Jan 20. doi: 10.1002/mds.28927.
    >> Share

  419. SUBRAMANIAN I, Mathur S, Oosterbaan A, Flanagan R, et al
    Unmet Needs of Women Living with Parkinson's Disease: Gaps and Controversies.
    Mov Disord. 2022 Jan 20. doi: 10.1002/mds.28921.
    >> Share

  420. MURATA H, Barnhill LM, Bronstein JM
    Air Pollution and the Risk of Parkinson's Disease: A Review.
    Mov Disord. 2022 Jan 19. doi: 10.1002/mds.28922.
    >> Share

  421. BUHMANN C, Lezius S, Potter-Nerger M, Gerloff C, et al
    Age-Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK-PD).
    Mov Disord. 2022 Jan 17. doi: 10.1002/mds.28909.
    >> Share

  422. COCHEN DE COCK V, Dotov D, Lacombe S, Picot MC, et al
    Classifying Idiopathic Rapid Eye Movement Sleep Behavior Disorder, Controls, and Mild Parkinson's Disease Using Gait Parameters.
    Mov Disord. 2022 Jan 17. doi: 10.1002/mds.28894.
    >> Share

  423. VAN DER ZEE S, Kanel P, Gerritsen MJJ, Boertien JM, et al
    Altered Cholinergic Innervation in De Novo Parkinson's Disease with and without Cognitive Impairment.
    Mov Disord. 2022 Jan 17. doi: 10.1002/mds.28913.
    >> Share

  424. MARTINEZ-VALBUENA I, Visanji NP, Olszewska DA, Sousa M, et al
    Combining Skin alpha-Synuclein Real-Time Quaking-Induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson's Disease.
    Mov Disord. 2022 Jan 12. doi: 10.1002/mds.28912.
    >> Share

  425. ISHIBASHI K, Miura Y, Wagatsuma K, Toyohara J, et al
    Adenosine A2A Receptor Occupancy by Caffeine After Coffee Intake in Parkinson's Disease.
    Mov Disord. 2022 Jan 9. doi: 10.1002/mds.28897.
    >> Share

  426. LEODORI G, De Bartolo MI, Guerra A, Fabbrini A, et al
    Motor Cortical Network Excitability in Parkinson's Disease.
    Mov Disord. 2022 Jan 9. doi: 10.1002/mds.28914.
    >> Share

  427. DOMENIGHETTI C, Sugier PE, Ashok Kumar Sreelatha A, Schulte C, et al
    Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study.
    Mov Disord. 2022 Jan 8. doi: 10.1002/mds.28902.
    >> Share

  428. VANEGAS-ARROYAVE N, Chen DF, Lauro PM, Norato G, et al
    Where Do Parkinson's Disease Patients Look while Walking?
    Mov Disord. 2022 Jan 8. doi: 10.1002/mds.28917.
    >> Share

  429. MERCHANT K, Sullivan J
    c-Abl Inhibitors as Disease-Modifying Therapies for Parkinson's Disease: Gaps and Opportunities.
    Mov Disord. 2022;37:3-5.
    >> Share

  430. LA MORGIA C, Romagnoli M, Pizza F, Biscarini F, et al
    Chromatic Pupillometry in Isolated Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2022;37:205-210.
    >> Share

    December 2021
  431. LEWIS SJG, Factor SA, Giladi N, Hallett M, et al
    Addressing the Challenges of Clinical Research for Freezing of Gait in Parkinson's Disease.
    Mov Disord. 2021 Dec 22. doi: 10.1002/mds.28837.
    >> Share

  432. BOHNEN NI, Costa RM, Dauer WT, Factor SA, et al
    Discussion of Research Priorities for Gait Disorders in Parkinson's Disease.
    Mov Disord. 2021 Dec 22. doi: 10.1002/mds.28883.
    >> Share

  433. GUTTUSO T JR, Sirica D, Tosun D, Zivadinov R, et al
    Thalamic Dorsomedial Nucleus Free Water Correlates with Cognitive Decline in Parkinson's Disease.
    Mov Disord. 2021 Dec 22. doi: 10.1002/mds.28886.
    >> Share

  434. BOSHKOVSKI T, Cohen-Adad J, Misic B, Arnulf I, et al
    The Myelin-Weighted Connectome in Parkinson's Disease.
    Mov Disord. 2021 Dec 22. doi: 10.1002/mds.28891.
    >> Share

  435. DEVIGNES Q, Bordier C, Viard R, Defebvre L, et al
    Resting-State Functional Connectivity in Frontostriatal and Posterior Cortical Subtypes in Parkinson's Disease-Mild Cognitive Impairment.
    Mov Disord. 2021 Dec 17. doi: 10.1002/mds.28888.
    >> Share

  436. LIN CH, Lin HY, Ho EP, Ke YC, et al
    Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice Through Activating TNF-alpha Pathway.
    Mov Disord. 2021 Dec 17. doi: 10.1002/mds.28890.
    >> Share

  437. ZOLFAGHARI S, Thomann AE, Lewandowski N, Trundell D, et al
    Self-Report versus Clinician Examination in Early Parkinson's Disease.
    Mov Disord. 2021 Dec 13. doi: 10.1002/mds.28884.
    >> Share

  438. BRUNO MK, Watanabe G, Ishikawa K, Chen JJ, et al
    Geographic Variation in Prescription Patterns of Parkinson's Disease Medications.
    Mov Disord. 2021 Dec 3. doi: 10.1002/mds.28880.
    >> Share

  439. RODRIGUEZ-ROJAS R, Pineda-Pardo JA, Manez-Miro J, Sanchez-Turel A, et al
    Functional Topography of the Human Subthalamic Nucleus: Relevance for Subthalamotomy in Parkinson's Disease.
    Mov Disord. 2021 Dec 3. doi: 10.1002/mds.28862.
    >> Share

  440. MACIAS-GARCIA D, Perinan MT, Munoz-Delgado L, Jesus S, et al
    Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations.
    Mov Disord. 2021 Dec 2. doi: 10.1002/mds.28863.
    >> Share

  441. GHIGLIERI V, Natale G
    Reply to: Rewiring Brains in Parkinson's Disease: The New Era of Brain Stimulation.
    Mov Disord. 2021;36:2979-2980.
    >> Share

  442. GARCIA AM, Orozco-Arroyave JR
    Reply to: "Does Cognitive Impairment Influence Motor Speech Performance in De Novo Parkinson's Disease".
    Mov Disord. 2021;36:2982-2983.
    >> Share

  443. RUSZ J, Tykalova T
    Does Cognitive Impairment Influence Motor Speech Performance in De Novo Parkinson's Disease?
    Mov Disord. 2021;36:2980-2982.
    >> Share

  444. SUPPA A
    Rewiring Brains in Parkinson's Disease: The New Era of Brain Stimulation.
    Mov Disord. 2021;36:2979.
    >> Share

  445. YSSELSTEIN D, Young TJ, Nguyen M, Padmanabhan S, et al
    Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity.
    Mov Disord. 2021;36:2719-2730.
    >> Share

  446. VERHAGEN METMAN L, Slavin KV, Rosenow JM, Vitek JL, et al
    More Than Just the Level of Consciousness: Comparing Asleep and Awake Deep Brain Stimulation.
    Mov Disord. 2021;36:2763-2766.
    >> Share

  447. FOIS AF, Mahant N, Vucic S, Fung VSC, et al
    Measuring Tremor-A Comparison of Automated Video Analysis, Neurophysiology, and Clinical Rating.
    Mov Disord. 2021;36:2962-2963.
    >> Share

    November 2021
  448. WERNER MH, Olanow CW
    Parkinson's Disease Modification through Abl Kinase Inhibition: An Opportunity.
    Mov Disord. 2021 Nov 23. doi: 10.1002/mds.28858.
    >> Share

  449. SCAMARCIA PG, Agosta F, Spinelli EG, Basaia S, et al
    Longitudinal White Matter Damage Evolution in Parkinson's Disease.
    Mov Disord. 2021 Nov 22. doi: 10.1002/mds.28864.
    >> Share

  450. SASIKUMAR S, Cohn M, Harmsen IE, Loh A, et al
    Single-Trajectory Multiple-Target Deep Brain Stimulation for Parkinsonian Mobility and Cognition.
    Mov Disord. 2021 Nov 22. doi: 10.1002/mds.28870.
    >> Share

  451. CHEN C, Mossman E, Malko P, McDonald D, et al
    Astrocytic Changes in Mitochondrial Oxidative Phosphorylation Protein Levels in Parkinson's Disease.
    Mov Disord. 2021 Nov 15. doi: 10.1002/mds.28849.
    >> Share

  452. COSENTINO C, Torres L, Velez M, Nunez Y, et al
    SARS-CoV-2 Vaccines and Motor Symptoms in Parkinson's Disease.
    Mov Disord. 2021 Nov 14. doi: 10.1002/mds.28851.
    >> Share

  453. VOGEL A, Claus I, Ahring S, Gruber D, et al
    Endoscopic Characteristics of Dysphagia in Multiple System Atrophy Compared to Parkinson's Disease.
    Mov Disord. 2021 Nov 13. doi: 10.1002/mds.28854.
    >> Share

  454. LANE EL, Harrison DJ, Ramos-Varas E, Hills R, et al
    Spontaneous Graft-Induced Dyskinesias Are Independent of 5-HT Neurons and Levodopa Priming in a Model of Parkinson's Disease.
    Mov Disord. 2021 Nov 12. doi: 10.1002/mds.28856.
    >> Share

  455. SURMEIER DJ, Nguyen JT, Lancki N, Venuto CS, et al
    Re-Analysis of the STEADY-PD II Trial-Evidence for Slowing the Progression of Parkinson's Disease.
    Mov Disord. 2021 Nov 12. doi: 10.1002/mds.28850.
    >> Share

  456. SURFACE M, Balwani M, Waters C, Haimovich A, et al
    Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease.
    Mov Disord. 2021 Nov 6. doi: 10.1002/mds.28846.
    >> Share

  457. ARPIN DJ, Mitchell T, Archer DB, Burciu RG, et al
    Diffusion Magnetic Resonance Imaging Detects Progression in Parkinson's Disease: A Placebo-Controlled Trial of Rasagiline.
    Mov Disord. 2021 Nov 1. doi: 10.1002/mds.28838.
    >> Share

  458. LESCHZINER AE, Reck-Peterson SL
    Structural Biology of LRRK2 and its Interaction with Microtubules.
    Mov Disord. 2021;36:2494-2504.
    >> Share

  459. MANOR B, Dagan M, Herman T, Gouskova NA, et al
    Multitarget Transcranial Electrical Stimulation for Freezing of Gait: A Randomized Controlled Trial.
    Mov Disord. 2021;36:2693-2698.
    >> Share

  460. LERCHE S, Sjodin S, Brinkmalm A, Blennow K, et al
    CSF Protein Level of Neurotransmitter Secretion, Synaptic Plasticity, and Autophagy in PD and DLB.
    Mov Disord. 2021;36:2595-2604.
    >> Share

  461. BORDERS JC, Sevitz JS, Curtis JA, Vanegas-Arroyave N, et al
    Sensorimotor Cough Dysfunction Is Prevalent and Pervasive in Progressive Supranuclear Palsy.
    Mov Disord. 2021;36:2624-2633.
    >> Share

    October 2021
  462. CORVOL JC, Azulay JP, Bosse B, Dauvilliers Y, et al
    THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial.
    Mov Disord. 2021 Oct 28. doi: 10.1002/mds.28840.
    >> Share

  463. CHARISIS S, Ntanasi E, Stamelou M, Xiromerisiou G, et al
    Plasma Glutathione and Prodromal Parkinson's Disease Probability.
    Mov Disord. 2021 Oct 25. doi: 10.1002/mds.28826.
    >> Share

  464. VAN RENSBURG ZJ, Abrahams S, Chetty D, Step K, et al
    The South African Parkinson's Disease Study Collection.
    Mov Disord. 2021 Oct 22. doi: 10.1002/mds.28828.
    >> Share

  465. SAMBIN S, Lavisse S, Decaix C, Pyatigorskaya N, et al
    Compensatory Mechanisms Nine Years Before Parkinson's Disease Conversion in a LRRK2 R1441H Family.
    Mov Disord. 2021 Oct 20. doi: 10.1002/mds.28833.
    >> Share

  466. KLARENDIC M, Kirbis M, Mojsovska E, Kavcic M, et al
    Bee Venom Does Not Reduce the Risk for Parkinson's Disease: Epidemiological Study among Beekeepers.
    Mov Disord. 2021 Oct 16. doi: 10.1002/mds.28820.
    >> Share

  467. TSUKITA K, Sakamaki-Tsukita H, Takahashi R
    Lower Circulating Lymphocyte Count Predicts ApoE epsilon4-Related Cognitive Decline in Parkinson's Disease.
    Mov Disord. 2021 Oct 13. doi: 10.1002/mds.28799.
    >> Share

  468. HUXFORD B, Haque T, Joseph AB, Simonet C, et al
    Parkinson's Disease and Type 2 Diabetes: HbA1c Is Associated with Motor and Cognitive Severity.
    Mov Disord. 2021 Oct 13. doi: 10.1002/mds.28829.
    >> Share

  469. JARAZO J, Barmpa K, Modamio J, Saraiva C, et al
    Parkinson's Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2-Hydroxypropyl-beta-Cyclodextrin Treatment.
    Mov Disord. 2021 Oct 12. doi: 10.1002/mds.28810.
    >> Share

  470. SCHIRINZI T, Maftei D, Ralli M, Greco A, et al
    Serum Substance P Is Increased in Parkinson's Disease and Correlates with Motor Impairment.
    Mov Disord. 2021 Oct 8. doi: 10.1002/mds.28824.
    >> Share

  471. MAGRINELLI F, Mehta S, Di Lazzaro G, Latorre A, et al
    Dissecting the Phenotype and Genotype of PLA2G6-Related Parkinsonism.
    Mov Disord. 2021 Oct 8. doi: 10.1002/mds.28807.
    >> Share

  472. PU JL, Jin CY, Wang ZX, Fang Y, et al
    Apolipoprotein E Genotype Contributes to Motor Progression in Parkinson's Disease.
    Mov Disord. 2021 Oct 6. doi: 10.1002/mds.28805.
    >> Share

  473. PIHLSTROM L, Fan CC, Frei O, Tan M, et al
    Genetic Stratification of Age-Dependent Parkinson's Disease Risk by Polygenic Hazard Score.
    Mov Disord. 2021 Oct 6. doi: 10.1002/mds.28808.
    >> Share

  474. JUCAITE A, Cselenyi Z, Kreisl WC, Rabiner EA, et al
    Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [(11) C]PBR28 and Machine Learning Analysis.
    Mov Disord. 2021 Oct 5. doi: 10.1002/mds.28814.
    >> Share

  475. GULER S, Gul T, Guler S, Haerle MC, et al
    Early-Onset Parkinson's Disease: A Novel Deletion Comprising the DJ-1 and TNFRSF9 Genes.
    Mov Disord. 2021 Oct 3. doi: 10.1002/mds.28812.
    >> Share

  476. CAMINITI SP, Carli G, Avenali M, Blandini F, et al
    Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations.
    Mov Disord. 2021 Oct 1. doi: 10.1002/mds.28818.
    >> Share

  477. KANG X, Ploner A, Roelstraete B, Khalili H, et al
    Reply to: "Association between Microscopic Colitis and Parkinson's Disease in a Swedish Population".
    Mov Disord. 2021;36:2453.
    >> Share

  478. ONG TL, Dal S, Williams LJ, Morales-Briceno H, et al
    \Association between Microscopic Colitis and Parkinson's Disease in a Swedish Population.
    Mov Disord. 2021;36:2452.
    >> Share

  479. GAN-OR Z, Wood NW
    Mendelian Randomization Studies: A Path to Better Understand Sex and Gender Differences in Parkinson's Disease?
    Mov Disord. 2021;36:2220-2222.
    >> Share

  480. NAMBU A
    Distinct Roles of the Dorsal Versus Ventral Subthalamic Nucleus.
    Mov Disord. 2021;36:2223.
    >> Share

  481. ERRO R, Mencacci NE, Bhatia KP
    The Emerging Role of Phosphodiesterases in Movement Disorders.
    Mov Disord. 2021;36:2225-2243.
    >> Share

  482. CAMACHO M, Greenland JC, Williams-Gray CH
    The Gastrointestinal Dysfunction Scale for Parkinson's Disease.
    Mov Disord. 2021;36:2358-2366.
    >> Share

    September 2021
  483. REYES-PEREZ P, Bandres-Ciga S
    Identifying Genetic Markers Associated with the Progression of Cognitive Decline in Parkinson's Disease: A Call Out for Replication.
    Mov Disord. 2021 Sep 30. doi: 10.1002/mds.28798.
    >> Share

  484. MILANOWSKI LM, Oshinaike O, Walton RL, Soto-Beasley AI, et al
    Screening of GBA Mutations in Nigerian Patients with Parkinson's Disease.
    Mov Disord. 2021 Sep 29. doi: 10.1002/mds.28803.
    >> Share

  485. EVIDENTE VGH, Evidente DH, Ortega SC, Levine TD, et al
    X-Linked Dystonia-Parkinsonism ("Lubag") May Present with Peripheral Synucleinopathy.
    Mov Disord. 2021 Sep 28. doi: 10.1002/mds.28801.
    >> Share

  486. REN Y, Jiang H, Pu J, Li L, et al
    Molecular Features of Parkinson's Disease in Patient-Derived Midbrain Dopaminergic Neurons.
    Mov Disord. 2021 Sep 26. doi: 10.1002/mds.28786.
    >> Share

  487. BUCHANAN SM, Richards M, Schott JM, Schrag A, et al
    Mild Parkinsonian Signs: A Systematic Review of Clinical, Imaging, and Pathological Associations.
    Mov Disord. 2021 Sep 25. doi: 10.1002/mds.28777.
    >> Share

  488. MAASS F, Michalke B, Willkommen D, Canaslan S, et al
    Cerebrospinal Fluid Iron-Ferritin Ratio as a Potential Progression Marker for Parkinson's Disease.
    Mov Disord. 2021 Sep 23. doi: 10.1002/mds.28790.
    >> Share

  489. OMER N, Giladi N, Gurevich T, Bar-Shira A, et al
    Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity.
    Mov Disord. 2021 Sep 22. doi: 10.1002/mds.28792.
    >> Share

  490. LAKE J, Reed X, Langston RG, Nalls MA, et al
    Coding and Noncoding Variation in LRRK2 and Parkinson's Disease Risk.
    Mov Disord. 2021 Sep 20. doi: 10.1002/mds.28787.
    >> Share

  491. RENNER H, Scholer HR, Bruder JM
    Combining Automated Organoid Workflows With Artificial Intelligence-Based Analyses: Opportunities to Build a New Generation of Interdisciplinary High-Throughput Screens for Parkinson's Disease and Beyond.
    Mov Disord. 2021 Sep 8. doi: 10.1002/mds.28775.
    >> Share

  492. POEWE W, Stocchi F, Arkadir D, Ebersbach G, et al
    Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study.
    Mov Disord. 2021 Sep 8. doi: 10.1002/mds.28758.
    >> Share

  493. MAILLET A, Metereau E, Tremblay L, Favre E, et al
    Serotonergic and Dopaminergic Lesions Underlying Parkinsonian Neuropsychiatric Signs.
    Mov Disord. 2021 Sep 8. doi: 10.1002/mds.28722.
    >> Share

  494. AAMODT WW, Waligorska T, Shen J, Tropea TF, et al
    Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease.
    Mov Disord. 2021 Sep 4. doi: 10.1002/mds.28779.
    >> Share

  495. LIN ZH, Zhang BR
    Striking While the Iron is Hot: The Role of Prosaposin (PSAP) in Parkinson's Disease.
    Mov Disord. 2021 Sep 3. doi: 10.1002/mds.28781.
    >> Share

  496. ELSAYED I, Foote IF
    Improving Diversity in Parkinson's Disease Genetics: Findings from the First-Ever Genome-Wide Association Study in Latinos.
    Mov Disord. 2021 Sep 2. doi: 10.1002/mds.28782.
    >> Share

  497. TERRACCIANO A, Aschwanden D, Stephan Y, Cerasa A, et al
    Reply to: "Is Conscientiousness Related to the Risk of Parkinson's Disease?"
    Mov Disord. 2021;36:2216.
    >> Share

  498. LUCA A, Nicoletti A, Zappia M
    Neuroticism and Risk of Parkinson's Disease: A Meta-Analysis.
    Mov Disord. 2021;36:2215.
    >> Share

  499. QUATTRONE A, Antonini A, Vaillancourt DE, Seppi K, et al
    Reply to: "Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy".
    Mov Disord. 2021;36:2208-2209.
    >> Share

  500. LIU H, Koros C, Stefanis L, Gasser T, et al
    Reply to: "alpha-Synuclein (SNCA) A30G Mutation as a Cause of a Complex Phenotype Without Parkinsonism".
    Mov Disord. 2021;36:2212-2213.
    >> Share

  501. RAU A, Jost WH, von der Warth R, Urbach H, et al
    Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy.
    Mov Disord. 2021;36:2207-2208.
    >> Share

  502. TAN S, Baggio D, Shortt J, Ko B, et al
    Cardiovascular Safety of Nilotinib in Parkinson's Disease.
    Mov Disord. 2021;36:2217.
    >> Share

  503. SOKRATOUS M, Breza M, Senkevich K, Gan-Or Z, et al
    alpha-Synuclein (SNCA) A30G Mutation as a Cause of a Complex Phenotype Without Parkinsonism.
    Mov Disord. 2021;36:2209-2212.
    >> Share

  504. ISHIMOTO T, Yamakado H
    Membranes and Organelle in Lewy Bodies: The Mastermind or the Bystander?
    Mov Disord. 2021;36:2026.
    >> Share

  505. MAJBOUR NK, Abdi IY, Dakna M, Wicke T, et al
    Cerebrospinal alpha-Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort.
    Mov Disord. 2021;36:2048-2056.
    >> Share

  506. ANDERSEN KB, Hansen AK, Damholdt MF, Horsager J, et al
    Reduced Synaptic Density in Patients with Lewy Body Dementia: An [(11) C]UCB-J PET Imaging Study.
    Mov Disord. 2021;36:2057-2065.
    >> Share

    August 2021
  507. LIU Y, Lawton MA, Lo C, Bowring F, et al
    Longitudinal Changes in Parkinson's Disease Symptoms with and Without Rapid Eye Movement Sleep Behavior Disorder: The Oxford Discovery Cohort Study.
    Mov Disord. 2021 Aug 26. doi: 10.1002/mds.28763.
    >> Share

  508. KAINAGA M, Shirota Y, Kodama S, Toda T, et al
    Effects of the Coronavirus Disease 2019 Pandemic on Motor Symptoms in Parkinson's Disease: An Observational Study.
    Mov Disord. 2021 Aug 25. doi: 10.1002/mds.28766.
    >> Share

  509. ONOFRJ M, Di Iorio A, Carrarini C, Russo M, et al
    Preexisting Bipolar Disorder Influences the Subsequent Phenotype of Parkinson's Disease.
    Mov Disord. 2021 Aug 24. doi: 10.1002/mds.28745.
    >> Share

  510. KUSTERS CDJ, Paul KC, Duarte Folle A, Keener AM, et al
    Increased Menopausal Age Reduces the Risk of Parkinson's Disease: A Mendelian Randomization Approach.
    Mov Disord. 2021 Aug 23. doi: 10.1002/mds.28760.
    >> Share

  511. CAMPESE N, Goebel G, Leys F, Ndayisaba JP, et al
    Orthostatic Hypotension in Parkinson's Disease: Do Height and Weight Matter?
    Mov Disord. 2021 Aug 23. doi: 10.1002/mds.28768.
    >> Share

  512. O'SHEA SA, Hickman RA, Cortes E, Vonsattel JP, et al
    Neuropathological Findings in a Case of Parkinsonism and Developmental Delay Associated with a Monoallelic Variant in PLXNA1.
    Mov Disord. 2021 Aug 20. doi: 10.1002/mds.28756.
    >> Share

  513. CIRNARU MD, Creus-Muncunill J, Nelson S, Lewis T, et al
    Striatal Cholinergic Dysregulation after Neonatal Decrease in X-Linked Dystonia Parkinsonism-Related TAF1 Isoforms.
    Mov Disord. 2021 Aug 17. doi: 10.1002/mds.28750.
    >> Share

  514. SIA MW, Foo JN, Saffari SE, Wong AS, et al
    Polygenic Risk Scores in a Prospective Parkinson's Disease Cohort.
    Mov Disord. 2021 Aug 17. doi: 10.1002/mds.28761.
    >> Share

  515. QI S, Yin P, Wang L, Qu M, et al
    Prevalence of Parkinson's Disease: A Community-Based Study in China.
    Mov Disord. 2021 Aug 14. doi: 10.1002/mds.28762.
    >> Share

  516. GARCIA AM, Arias-Vergara T, C Vasquez-Correa J, Noth E, et al
    Cognitive Determinants of Dysarthria in Parkinson's Disease: An Automated Machine Learning Approach.
    Mov Disord. 2021 Aug 14. doi: 10.1002/mds.28751.
    >> Share

  517. LE HERON C, MacAskill M, Mason D, Dalrymple-Alford J, et al
    A Multi-Step Model of Parkinson's Disease Pathogenesis.
    Mov Disord. 2021 Aug 10. doi: 10.1002/mds.28719.
    >> Share

  518. ERRO R, Buonomo AR, Barone P, Pellecchia MT, et al
    Severe dyskinesia after administration of SARS-CoV2 mRNA vaccine in Parkinson Disease.
    Mov Disord. 2021 Aug 9. doi: 10.1002/mds.28772.
    >> Share

  519. OLANOW CW, Poewe W, Rascol O, Stocchi F, et al
    On-Demand Therapy for OFF Episodes in Parkinson's Disease.
    Mov Disord. 2021 Aug 7. doi: 10.1002/mds.28726.
    >> Share

  520. SCHAEFFER E, Toedt I, Kohler S, Rogge A, et al
    Risk Disclosure in Prodromal Parkinson's Disease.
    Mov Disord. 2021 Aug 5. doi: 10.1002/mds.28723.
    >> Share

  521. OKUNOYE O, Horsfall L, Marston L, Walters K, et al
    Mortality of People with Parkinson's Disease in a Large UK-Based Cohort Study: Time Trends and Relationship to Disease Duration.
    Mov Disord. 2021 Aug 5. doi: 10.1002/mds.28727.
    >> Share

  522. MARKAKI I, Ntetsika T, Svenningsson P
    Reply to: "HbA1c and Motor Outcome in Parkinson's Disease in the Mark-PD Study".
    Mov Disord. 2021;36:1993.
    >> Share

  523. MONJE MHG, Sanchez-Ferro A, Pineda-Pardo JA, Vela-Desojo L, et al
    Reply to: Motor Features in a Peruvian Cohort of Parkinson's Disease Patients.
    Mov Disord. 2021;36:1994-1995.
    >> Share

  524. TORRES L, Velez M, Suarez R, Nunez Y, et al
    Motor Features in a Peruvian Cohort of Parkinson's Disease Patients.
    Mov Disord. 2021;36:1994.
    >> Share

  525. ZITTEL S, Uyar M, Lezius S, Gerloff C, et al
    HbA1c and Motor Outcome in Parkinson's Disease in the Mark-PD Study.
    Mov Disord. 2021;36:1991-1992.
    >> Share

  526. ZECH M, Jech R, Boesch S, Skorvanek M, et al
    Scoring Algorithm-Based Genomic Testing in Dystonia: A Prospective Validation Study.
    Mov Disord. 2021;36:1959-1964.
    >> Share

  527. KOSS DJ, Campesan S, Giorgini F, Outeiro TF, et al
    Dysfunction of RAB39B-Mediated Vesicular Trafficking in Lewy Body Diseases.
    Mov Disord. 2021;36:1744-1758.
    >> Share

  528. FASANO A, Gurevich T, Jech R, Kovacs N, et al
    Concomitant Medication Usage with Levodopa-Carbidopa Intestinal Gel: Results from the COSMOS Study.
    Mov Disord. 2021;36:1853-1862.
    >> Share

  529. KIM R, Lee JY, Kim YK, Kim H, et al
    Longitudinal Changes in Isolated Rapid Eye Movement Sleep Behavior Disorder-Related Metabolic Pattern Expression.
    Mov Disord. 2021;36:1889-1898.
    >> Share

    July 2021
  530. REN X, Lin J, Stebbins GT, Goetz CG, et al
    Prognostic Modeling of Parkinson's Disease Progression Using Early Longitudinal Patterns of Change.
    Mov Disord. 2021 Jul 30. doi: 10.1002/mds.28730.
    >> Share

  531. LAANSMA MA, Bright JK, Al-Bachari S, Anderson TJ, et al
    International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease.
    Mov Disord. 2021 Jul 20. doi: 10.1002/mds.28706.
    >> Share

  532. SARASSO E, Agosta F, Piramide N, Gardoni A, et al
    Action Observation and Motor Imagery Improve Dual Task in Parkinson's Disease: A Clinical/fMRI Study.
    Mov Disord. 2021 Jul 19. doi: 10.1002/mds.28717.
    >> Share

  533. GROS P, Wang X, Guan J, Lang AE, et al
    Exposure to Phosphoglycerate Kinase 1 Activators and Incidence of Parkinson's Disease.
    Mov Disord. 2021 Jul 9. doi: 10.1002/mds.28712.
    >> Share

  534. CONCHA-MARAMBIO L, Farris CM, Holguin B, Ma Y, et al
    Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression.
    Mov Disord. 2021 Jul 8. doi: 10.1002/mds.28715.
    >> Share

  535. FREIRE-ALVAREZ E, Kurca E, Lopez Manzanares L, Pekkonen E, et al
    Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial.
    Mov Disord. 2021 Jul 8. doi: 10.1002/mds.28703.
    >> Share

  536. MULLER-NEDEBOCK AC, Komolafe MA, Fawale MB, Carr JA, et al
    Copy Number Variation in Parkinson's Disease: An Update from Sub-Saharan Africa.
    Mov Disord. 2021 Jul 6. doi: 10.1002/mds.28710.
    >> Share

  537. SCHILLING M, Lill CM
    MicroRNAs as Molecular Biomarkers for Parkinson's Disease Progression.
    Mov Disord. 2021 Jul 5. doi: 10.1002/mds.28700.
    >> Share

  538. CHOONG CJ, Kimura Y, Mochizuki H
    Disturbed Mitochondria-Lysosome Crosstalk in GBA1-Associated Parkinson's Disease.
    Mov Disord. 2021 Jul 1. doi: 10.1002/mds.28693.
    >> Share

  539. RASCOL O, Cochen de Cock V, Pavy-Le Traon A, Foubert-Samier A, et al
    Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial.
    Mov Disord. 2021;36:1704-1711.
    >> Share

  540. SHILL HA, Zhang N, Driver-Dunckley E, Mehta S, et al
    Olfaction in Neuropathologically Defined Progressive Supranuclear Palsy.
    Mov Disord. 2021;36:1700-1704.
    >> Share

  541. PERKINS JE, Janzen A, Bernhard FP, Wilhelm K, et al
    Saccade, Pupil, and Blink Responses in Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2021;36:1720-1726.
    >> Share

  542. DE ALMEIDA CMO, Brito MMC, Bosaipo NB, Pimentel AV, et al
    Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2021;36:1711-1715.
    >> Share

  543. WITTKE C, Petkovic S, Dobricic V, Schaake S, et al
    Genotype-Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review.
    Mov Disord. 2021;36:1499-1510.
    >> Share

    June 2021
  544. VIDENOVIC A, Amara AW, Comella C, Schweitzer PK, et al
    Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial.
    Mov Disord. 2021 Jun 30. doi: 10.1002/mds.28702.
    >> Share

  545. PATEL SG, Buchanan CM, Mulroy E, Simpson M, et al
    Potential PINK1 Founder Effect in Polynesia Causing Early-Onset Parkinson's Disease.
    Mov Disord. 2021 Jun 22. doi: 10.1002/mds.28665.
    >> Share

  546. FIORENZATO E, Antonini A, Bisiacchi P, Weis L, et al
    Asymmetric Dopamine Transporter Loss Affects Cognitive and Motor Progression in Parkinson's Disease.
    Mov Disord. 2021 Jun 14. doi: 10.1002/mds.28682.
    >> Share

  547. NIGAM M, Ayadi I, Noiray C, Branquino-Bras AC, et al
    Sweet or Bland Dreams? Taste Loss in Isolated REM-Sleep Behavior Disorder and Parkinson's Disease.
    Mov Disord. 2021 Jun 12. doi: 10.1002/mds.28692.
    >> Share

  548. GELPI E, Haberler C, Micko A, Polt A, et al
    Focal Subthalamic Atrophy After Long-Term Deep Brain Stimulation in Parkinson's Disease.
    Mov Disord. 2021 Jun 12. doi: 10.1002/mds.28653.
    >> Share

  549. MAITI B, Rawson KS, Tanenbaum AB, Koller JM, et al
    Functional Connectivity of Vermis Correlates with Future Gait Impairments in Parkinson's Disease.
    Mov Disord. 2021 Jun 10. doi: 10.1002/mds.28684.
    >> Share

  550. MUNOZ-DELGADO L, Macias-Garcia D, Jesus S, Martin-Rodriguez JF, et al
    Peripheral Immune Profile and Neutrophil-to-Lymphocyte Ratio in Parkinson's Disease.
    Mov Disord. 2021 Jun 8. doi: 10.1002/mds.28685.
    >> Share

  551. SEGER AD, Farrher E, Doppler CEJ, Gogishvili A, et al
    Putaminal y-Aminobutyric Acid Modulates Motor Response to Dopaminergic Therapy in Parkinson's Disease.
    Mov Disord. 2021 Jun 7. doi: 10.1002/mds.28674.
    >> Share

  552. HAMID E, Ayele BA, Massi DG, Ben Sassi S, et al
    Availability of Therapies and Services for Parkinson's Disease in Africa: A Continent-Wide Survey.
    Mov Disord. 2021 Jun 3. doi: 10.1002/mds.28669.
    >> Share

  553. ISONAKA R, Goldstein DS, Zhu W, Yoon E, et al
    alpha-Synuclein Deposition in Sympathetic Nerve Fibers in Genetic Forms of Parkinson's Disease.
    Mov Disord. 2021 Jun 2. doi: 10.1002/mds.28667.
    >> Share

  554. MATHUR S
    Counting What Counts: How to Reach Outcomes That Truly Matter to Parkinson's Patients.
    Mov Disord. 2021;36:1290-1292.
    >> Share

    May 2021
  555. CARVALHO V, Ferreira JJ, Correia Guedes L
    Tremor and Parkinsonism in Chromosomopathies - A Systematic Review.
    Mov Disord. 2021 May 31. doi: 10.1002/mds.28663.
    >> Share

  556. CONEYS R, Storm CS, Kia DA, Almramhi M, et al
    Mendelian Randomisation Finds No Causal Association between Urate and Parkinson's Disease Progression.
    Mov Disord. 2021 May 31. doi: 10.1002/mds.28662.
    >> Share

  557. FEARON C, Mikulis DJ, Lang AE
    Parkinsonism as a Sequela of SARS-CoV-2 Infection: Pure Hypoxic Injury or Additional COVID-19-Related Response?
    Mov Disord. 2021 May 27. doi: 10.1002/mds.28656.
    >> Share

  558. BOUALI-BENAZZOUZ R, Benazzouz A
    Covid-19 Infection and Parkinsonism: Is There a Link?
    Mov Disord. 2021 May 27. doi: 10.1002/mds.28680.
    >> Share

  559. ORSO B, Arnaldi D, Girtler N, Brugnolo A, et al
    Dopaminergic and Serotonergic Degeneration and Cortical [(18) F]Fluorodeoxyglucose Positron Emission Tomography in De Novo Parkinson's Disease.
    Mov Disord. 2021 May 22. doi: 10.1002/mds.28654.
    >> Share

  560. DEAN DN, Lee JC
    Linking Parkinson's Disease and Melanoma: Interplay Between alpha-Synuclein and Pmel17 Amyloid Formation.
    Mov Disord. 2021 May 22. doi: 10.1002/mds.28655.
    >> Share

  561. SCHWEDHELM E, Englisch C, Niemann L, Lezius S, et al
    Sphingosine-1-Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK-PD).
    Mov Disord. 2021 May 19. doi: 10.1002/mds.28652.
    >> Share

  562. TOFFOLI M, Higgins A, Lee C, Koletsi S, et al
    Intronic Haplotypes in the GBA Gene Do Not Predict Age at Diagnosis of Parkinson's Disease.
    Mov Disord. 2021 May 19. doi: 10.1002/mds.28616.
    >> Share

  563. STUENDL A, Kraus T, Chatterjee M, Zapke B, et al
    alpha-Synuclein in Plasma-Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease.
    Mov Disord. 2021 May 18. doi: 10.1002/mds.28639.
    >> Share

  564. O'SULLIVAN JM, den Heijer JM, Groeneveld GJ, Cooper AA, et al
    Intronic Haplotypes in GBA Modify Age at Diagnosis of Parkinson's: Replication in a Subgroup.
    Mov Disord. 2021 May 18. doi: 10.1002/mds.28620.
    >> Share

  565. HAN F, Brown GL, Zhu Y, Belkin-Rosen AE, et al
    Decoupling of Global Brain Activity and Cerebrospinal Fluid Flow in Parkinson's Disease Cognitive Decline.
    Mov Disord. 2021 May 17. doi: 10.1002/mds.28643.
    >> Share

  566. MORLEY D, Dummett S, Kelly L, Jenkinson C, et al
    Development of an Exercise-Specific Parkinson's Disease Questionnaire: The PDQ-Exercise.
    Mov Disord. 2021 May 15. doi: 10.1002/mds.28644.
    >> Share

  567. MARRAS C, Mills KA, Eberly S, Oakes D, et al
    Longitudinal Change in Quality of Life in Neurological Disorders Measures Over 3 Years in Patients With Early Parkinson's Disease.
    Mov Disord. 2021 May 13. doi: 10.1002/mds.28641.
    >> Share

  568. RICCIARDI L, Fischer P, Mostofi A, Tinkhauser G, et al
    Neurophysiological Correlates of Trait Impulsivity in Parkinson's Disease.
    Mov Disord. 2021 May 13. doi: 10.1002/mds.28625.
    >> Share

  569. ESTIAR MA, Senkevich K, Yu E, Varghaei P, et al
    Lack of Causal Effects or Genetic Correlation between Restless Legs Syndrome and Parkinson's Disease.
    Mov Disord. 2021 May 11. doi: 10.1002/mds.28640.
    >> Share

  570. COLLOBY SJ, Nathan PJ, Bakker G, Lawson RA, et al
    Spatial Covariance of Cholinergic Muscarinic M1 /M4 Receptors in Parkinson's Disease.
    Mov Disord. 2021 May 11. doi: 10.1002/mds.28564.
    >> Share

  571. NAITO T, Satake W, Ogawa K, Suzuki K, et al
    Trans-Ethnic Fine-Mapping of the Major Histocompatibility Complex Region Linked to Parkinson's Disease.
    Mov Disord. 2021 May 11. doi: 10.1002/mds.28583.
    >> Share

  572. BARBUTI PA, Barker RA, Brundin P, Przedborski S, et al
    Recent Advances in the Development of Stem-Cell-Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease.
    Mov Disord. 2021 May 8. doi: 10.1002/mds.28628.
    >> Share

  573. IWAKI H, Leonard HL, Makarious MB, Bookman M, et al
    Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource.
    Mov Disord. 2021 May 7. doi: 10.1002/mds.28549.
    >> Share

  574. DI LAZZARO G, Magrinelli F, Estevez-Fraga C, Valente EM, et al
    X-Linked Parkinsonism: Phenotypic and Genetic Heterogeneity.
    Mov Disord. 2021 May 7. doi: 10.1002/mds.28565.
    >> Share

  575. MCINTOSH E, Kent S, Gray A, Clarke CE, et al
    Cost-Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's Disease.
    Mov Disord. 2021 May 7. doi: 10.1002/mds.28623.
    >> Share

  576. MIRELMAN A, Ben Or Frank M, Melamed M, Granovsky L, et al
    Detecting Sensitive Mobility Features for Parkinson's Disease Stages Via Machine Learning.
    Mov Disord. 2021 May 6. doi: 10.1002/mds.28631.
    >> Share

  577. KAASINEN V, Vahlberg T, Stoessl AJ, Strafella AP, et al
    Dopamine Receptors in Parkinson's Disease: A Meta-Analysis of Imaging Studies.
    Mov Disord. 2021 May 6. doi: 10.1002/mds.28632.
    >> Share

  578. KREMER T, Taylor KI, Siebourg-Polster J, Gerken T, et al
    Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease.
    Mov Disord. 2021 May 4. doi: 10.1002/mds.28608.
    >> Share

  579. SCHERBAUM R, Kwon EH, Richter D, Bartig D, et al
    Clinical Profiles and Mortality of COVID-19 Inpatients with Parkinson's Disease in Germany.
    Mov Disord. 2021 May 4. doi: 10.1002/mds.28586.
    >> Share

  580. MESTRE TA, Macklin EA, Ascherio A, Ferreira JJ, et al
    Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease.
    Mov Disord. 2021 May 4. doi: 10.1002/mds.28630.
    >> Share

  581. SCOTT GD, Lim MM, Drake MG, Woltjer R, et al
    Onset of Skin, Gut, and Genitourinary Prodromal Parkinson's Disease: A Study of 1.5 Million Veterans.
    Mov Disord. 2021 May 3. doi: 10.1002/mds.28636.
    >> Share

  582. KIEBURTZ K, Olanow CW
    Reply to: "A New Approach to the Development of Disease-Modifying Therapies for PD".
    Mov Disord. 2021;36:1281-1282.
    >> Share

  583. SIMON DK
    A New Approach to the Development of Disease-Modifying Therapies for PD.
    Mov Disord. 2021;36:1281.
    >> Share

  584. LERCHE S, Schulte C, Wurster I, Machetanz G, et al
    The Mutation Matters: CSF Profiles of GCase, Sphingolipids, alpha-Synuclein in PDGBA.
    Mov Disord. 2021;36:1216-1228.
    >> Share

    April 2021
  585. YILMAZ R, Suenkel U, Postuma RB, Heinzel S, et al
    Comparing the Two Prodromal Parkinson's Disease Research Criteria-Lessons for Future Studies.
    Mov Disord. 2021 Apr 30. doi: 10.1002/mds.28637.
    >> Share

  586. SARANZA G, Villanueva EQ 3rd, Lang AE
    Preferences for Communication About End-of-Life Care in Atypical Parkinsonism.
    Mov Disord. 2021 Apr 28. doi: 10.1002/mds.28633.
    >> Share

  587. HUYNH B, Fu Y, Kirik D, Shine JM, et al
    Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease.
    Mov Disord. 2021 Apr 26. doi: 10.1002/mds.28615.
    >> Share

  588. TSUNEMI T, Oyama G, Saiki S, Hatano T, et al
    Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review.
    Mov Disord. 2021 Apr 25. doi: 10.1002/mds.28595.
    >> Share

  589. LETA V, Rodriguez-Violante M, Abundes A, Rukavina K, et al
    Parkinson's disease and Post-COVID-19 syndrome: The Parkinson's Long-COVID spectrum.
    Mov Disord. 2021 Apr 22. doi: 10.1002/mds.28622.
    >> Share

  590. LI C, Ou R, Chen Y, Gu X, et al
    Genetic Modifiers of Age at Onset for Parkinson's Disease in Asians: A Genome-Wide Association Study.
    Mov Disord. 2021 Apr 21. doi: 10.1002/mds.28621.
    >> Share

  591. CHEN Y, Wu W, Zhao S, Lv X, et al
    Increased Accumulation of alpha-Synuclein in Inflamed Appendices of Parkinson's Disease Patients.
    Mov Disord. 2021 Apr 20. doi: 10.1002/mds.28553.
    >> Share

  592. JOHNSON LA, Aman JE, Yu Y, Escobar Sanabria D, et al
    High-Frequency Oscillations in the Pallidum: A Pathophysiological Biomarker in Parkinson's Disease?
    Mov Disord. 2021 Apr 13. doi: 10.1002/mds.28566.
    >> Share

  593. SOARES C, Carneiro DR, Dias R, Ferreira D, et al
    Behind the mask: recognizing facial features of Parkinson's disease during the COVID-19 pandemic.
    Mov Disord. 2021 Apr 9. doi: 10.1002/mds.28619.
    >> Share

  594. ZAHED H, Zuzuarregui JRP, Gilron R, Denison T, et al
    The Neurophysiology of Sleep in Parkinson's Disease.
    Mov Disord. 2021 Apr 7. doi: 10.1002/mds.28562.
    >> Share

  595. LIM SH, Ferdousi M, Kalteniece A, Mahfoud ZR, et al
    Corneal Confocal Microscopy Identifies Parkinson's Disease with More Rapid Motor Progression.
    Mov Disord. 2021 Apr 7. doi: 10.1002/mds.28602.
    >> Share

  596. JIANG C, Hopfner F, Berg D, Hu MT, et al
    Validation of alpha-Synuclein in L1CAM-Immunocaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes.
    Mov Disord. 2021 Apr 7. doi: 10.1002/mds.28591.
    >> Share

  597. KOOHI N, Bancroft MJ, Patel J, Castro P, et al
    Saccadic Bradykinesia in Parkinson's Disease: Preliminary Observations.
    Mov Disord. 2021 Apr 6. doi: 10.1002/mds.28609.
    >> Share

  598. TERRACCIANO A, Aschwanden D, Stephan Y, Cerasa A, et al
    Neuroticism and Risk of Parkinson's Disease: A Meta-Analysis.
    Mov Disord. 2021 Apr 4. doi: 10.1002/mds.28575.
    >> Share

  599. UEDA J, Uemura N, Sawamura M, Taguchi T, et al
    Perampanel Inhibits alpha-Synuclein Transmission in Parkinson's Disease Models.
    Mov Disord. 2021 Apr 4. doi: 10.1002/mds.28558.
    >> Share

  600. NIJHUIS FAP, Esselink R, de Bie RMA, Groenewoud H, et al
    Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta-Analysis.
    Mov Disord. 2021 Apr 2. doi: 10.1002/mds.28599.
    >> Share

  601. HELMICH RC, Van den Berg KRE, Panyakaew P, Cho HJ, et al
    Cerebello-Cortical Control of Tremor Rhythm and Amplitude in Parkinson's Disease.
    Mov Disord. 2021 Apr 1. doi: 10.1002/mds.28603.
    >> Share

  602. GUTTLER C, Nikulin VV, van Riesen C
    Reply to: "Levodopa-Induced Dyskinesia Is Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism".
    Mov Disord. 2021;36:1045-1047.
    >> Share

  603. SCHMIDT SL, Grill WM
    Levodopa-Induced Dyskinesia Is Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
    Mov Disord. 2021;36:1044-1045.
    >> Share

  604. NEUMANN WJ, Rodriguez-Oroz MC
    Machine Learning Will Extend the Clinical Utility of Adaptive Deep Brain Stimulation.
    Mov Disord. 2021;36:796-799.
    >> Share

  605. RUSZ J, Tykalova T, Ramig LO, Tripoliti E, et al
    Guidelines for Speech Recording and Acoustic Analyses in Dysarthrias of Movement Disorders.
    Mov Disord. 2021;36:803-814.
    >> Share

  606. GEORGIEV D, Roskar S, Cus A, Wilkinson L, et al
    STN-DBS Increases Proactive but Not Retroactive Interference During Verbal Learning in PD.
    Mov Disord. 2021;36:1010-1015.
    >> Share

  607. OSHIMA S, Fushimi Y, Okada T, Nakajima S, et al
    Neuromelanin-Sensitive Magnetic Resonance Imaging Using DANTE Pulse.
    Mov Disord. 2021;36:874-882.
    >> Share

  608. BOOTH S, Ramadan A, Zhang D, Lu L, et al
    The Vasomotor Response to Dopamine Is Altered in the Rat Model of l-dopa-Induced Dyskinesia.
    Mov Disord. 2021;36:938-947.
    >> Share

    March 2021
  609. VISANJI NP, Lang AE
    Call the Plumber: Impaired Meningeal Lymphatic Drainage in Parkinson's Disease.
    Mov Disord. 2021 Mar 30. doi: 10.1002/mds.28590.
    >> Share

  610. KLUGER BM, Dolhun R, Sumrall M, Hall K, et al
    Palliative Care and Parkinson's Disease: Time to Move Beyond Cancer.
    Mov Disord. 2021 Mar 30. doi: 10.1002/mds.28556.
    >> Share

  611. SCHIESS M, Suescun J, Doursout MF, Adams C, et al
    Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease.
    Mov Disord. 2021 Mar 27. doi: 10.1002/mds.28582.
    >> Share

  612. KANG X, Ploner A, Roelstraete B, Khalili H, et al
    Association between Microscopic Colitis and Parkinson's Disease in a Swedish Population.
    Mov Disord. 2021 Mar 25. doi: 10.1002/mds.28594.
    >> Share

  613. GROVER S, Kumar-Sreelatha AA, Bobbili DR, May P, et al
    Replication of a Novel Parkinson's Locus in a European Ancestry Population.
    Mov Disord. 2021 Mar 24. doi: 10.1002/mds.28546.
    >> Share

  614. ABRAHAM DS, Pham Nguyen TP, Willis AW
    Claims-Based Frailty and Outcomes: Applying an Aging Measure to Older Adults with Parkinson's Disease.
    Mov Disord. 2021 Mar 23. doi: 10.1002/mds.28561.
    >> Share

  615. YAO CW, Saha-Chaudhuri P, Zolfaghari S, Pelletier A, et al
    Phenoconversion from Possible REM Sleep Behavior to Parkinsonism in the Population-Based CLSA.
    Mov Disord. 2021 Mar 22. doi: 10.1002/mds.28571.
    >> Share

  616. SALARI M, Etemadifar M, Zali A, Medghalchi A, et al
    Seroprevalence of SARS-CoV-2 in Parkinson's Disease Patients: A Case-Control Study.
    Mov Disord. 2021 Mar 17. doi: 10.1002/mds.28580.
    >> Share

  617. MARINI K, Seppi K, Tschiderer L, Kiechl S, et al
    Application of the Updated Movement Disorder Society Criteria for Prodromal Parkinson's Disease to a Population-Based 10-Year Study.
    Mov Disord. 2021 Mar 17. doi: 10.1002/mds.28570.
    >> Share

  618. CANONICO M, Pesce G, Bonaventure A, Le Noan-Laine M, et al
    Increased Risk of Parkinson's Disease in Women after Bilateral Oophorectomy.
    Mov Disord. 2021 Mar 16. doi: 10.1002/mds.28563.
    >> Share

  619. DOBKIN RD, Mann SL, Weintraub D, Rodriguez KM, et al
    Innovating Parkinson's Care: A Randomized Controlled Trial of Telemedicine Depression Treatment.
    Mov Disord. 2021 Mar 12. doi: 10.1002/mds.28548.
    >> Share

  620. GAURAV R, Yahia-Cherif L, Pyatigorskaya N, Mangone G, et al
    Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker.
    Mov Disord. 2021 Mar 10. doi: 10.1002/mds.28531.
    >> Share

  621. CHOHAN H, Senkevich K, Patel RK, Bestwick JP, et al
    Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression.
    Mov Disord. 2021 Mar 8. doi: 10.1002/mds.28551.
    >> Share

  622. DUYSENS J, Nonnekes J
    Parkinson's Kinesia Paradoxa Is Not a Paradox.
    Mov Disord. 2021 Mar 3. doi: 10.1002/mds.28550.
    >> Share

  623. CLAUS I, Muhle P, Czechowski J, Ahring S, et al
    Expiratory Muscle Strength Training for Therapy of Pharyngeal Dysphagia in Parkinson's Disease.
    Mov Disord. 2021 Mar 2. doi: 10.1002/mds.28552.
    >> Share

  624. FEARON C, Lang AE, Espay AJ
    The Logic and Pitfalls of Parkinson's Disease as "Brain-First" Versus "Body-First" Subtypes.
    Mov Disord. 2021;36:594-598.
    >> Share

  625. BORGHAMMER P, Horsager J
    The Logic and Pitfalls of Parkinson's as Brain- Versus Body-First Subtypes.
    Mov Disord. 2021;36:785-786.
    >> Share

  626. FEARON C, Lang AE, J Espay A
    Reply to: "The Logic and Pitfalls of Parkinson's as Brain- Versus Body-First Subtypes".
    Mov Disord. 2021;36:786-787.
    >> Share

  627. SARTER M, Avila C, Kucinski A, Donovan E, et al
    Make a Left Turn: Cortico-Striatal Circuitry Mediating the Attentional Control of Complex Movements.
    Mov Disord. 2021;36:535-546.
    >> Share

  628. YOUNCE JR, Campbell MC, Hershey T, Tanenbaum AB, et al
    Resting-State Functional Connectivity Predicts STN DBS Clinical Response.
    Mov Disord. 2021;36:662-671.
    >> Share

  629. POLISSIDIS A, Koronaiou M, Kollia V, Koronaiou E, et al
    Psychosis-Like Behavior and Hyperdopaminergic Dysregulation in Human alpha-Synuclein BAC Transgenic Rats.
    Mov Disord. 2021;36:716-728.
    >> Share

  630. HANSS Z, Larsen SB, Antony P, Mencke P, et al
    Mitochondrial and Clearance Impairment in p.D620N VPS35 Patient-Derived Neurons.
    Mov Disord. 2021;36:704-715.
    >> Share

    February 2021
  631. DE MICCO R, Agosta F, Basaia S, Siciliano M, et al
    Functional Connectomics and Disease Progression in Drug-Naive Parkinson's Disease Patients.
    Mov Disord. 2021 Feb 27. doi: 10.1002/mds.28541.
    >> Share

  632. BURTSCHER J, Syed MMK, Lashuel HA, Millet GP, et al
    Hypoxia Conditioning as a Promising Therapeutic Target in Parkinson's Disease?
    Mov Disord. 2021 Feb 27. doi: 10.1002/mds.28544.
    >> Share

  633. MARKAKI I, Ntetsika T, Sorjonen K, Svenningsson P, et al
    Euglycemia Indicates Favorable Motor Outcome in Parkinson's Disease.
    Mov Disord. 2021 Feb 26. doi: 10.1002/mds.28545.
    >> Share

  634. CHAHINE LM, Zhu X, Ehrenkranz R, Chen H, et al
    Changes in Self-Reported Energy Levels in Prodromal Parkinson's Disease.
    Mov Disord. 2021 Feb 26. doi: 10.1002/mds.28535.
    >> Share

  635. KAKAR RS, Pastor JV, Moe OW, Ambrosio F, et al
    Peripheral Klotho and Parkinson's Disease.
    Mov Disord. 2021 Feb 25. doi: 10.1002/mds.28530.
    >> Share

  636. MOONEN AJH, Mulders AEP, Defebvre L, Duits A, et al
    Cognitive Behavioral Therapy for Anxiety in Parkinson's Disease: A Randomized Controlled Trial.
    Mov Disord. 2021 Feb 22. doi: 10.1002/mds.28533.
    >> Share

  637. AVENALI M, Cerri S, Ongari G, Ghezzi C, et al
    Profiling the Biochemical Signature of GBA-Related Parkinson's Disease in Peripheral Blood Mononuclear Cells.
    Mov Disord. 2021 Feb 22. doi: 10.1002/mds.28496.
    >> Share

  638. LIU H, Koros C, Strohaker T, Schulte C, et al
    A Novel SNCA A30G Mutation Causes Familial Parkinson's Disease.
    Mov Disord. 2021 Feb 22. doi: 10.1002/mds.28534.
    >> Share

  639. SONG S, Luo Z, Li C, Huang X, et al
    Changes in Body Composition Before and After Parkinson's Disease Diagnosis.
    Mov Disord. 2021 Feb 22:e28536. doi: 10.1002/mds.28536.
    >> Share

  640. AEED F, Cermak N, Schiller J, Schiller Y, et al
    Intrinsic Disruption of the M1 Cortical Network in a Mouse Model of Parkinson's Disease.
    Mov Disord. 2021 Feb 19. doi: 10.1002/mds.28538.
    >> Share

  641. KLEINER G, Fernandez HH, Chou KL, Fasano A, et al
    Non-Motor Fluctuations in Parkinson's Disease: Validation of the Non-Motor Fluctuation Assessment Questionnaire.
    Mov Disord. 2021 Feb 15. doi: 10.1002/mds.28507.
    >> Share

  642. GALPER J, Balwani M, Fahn S, Waters C, et al
    Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers With and Without Parkinson Disease.
    Mov Disord. 2021 Feb 11. doi: 10.1002/mds.28525.
    >> Share

  643. BRIGHT JM, Carlisle HJ, Toda AMA, Murphy M, et al
    Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor.
    Mov Disord. 2021 Feb 11. doi: 10.1002/mds.28490.
    >> Share

  644. PAZ RM, Tubert C, Stahl AM, Amarillo Y, et al
    Levodopa Causes Striatal Cholinergic Interneuron Burst-Pause Activity in Parkinsonian Mice.
    Mov Disord. 2021 Feb 6. doi: 10.1002/mds.28516.
    >> Share

  645. ANTAR T, Iwaki H, B Singleton A
    Reply to: 'Letter to the Editor on "Sex Differences in Parkinson's Disease Phenotype and Caregiving Disparities"'.
    Mov Disord. 2021;36:527-528.
    >> Share

  646. OUTEIRO TF, Krisko A
    Reply to: "Parkinson's Disease and COVID-19: Do We Need to Be More Patient?"
    Mov Disord. 2021;36:278-279.
    >> Share

  647. GONZALEZ-LATAPI P, Fearon C, Fasano A, Lang AE, et al
    Parkinson's Disease and COVID-19: Do We Need to Be More Patient?
    Mov Disord. 2021;36:277.
    >> Share

  648. DE LA ROSA T, Amado Scerni D, Scorza FA
    Sex Differences in Parkinson's Disease Phenotype and Caregiving Disparities.
    Mov Disord. 2021;36:526.
    >> Share

  649. HO GPH, Ramalingam N, Imberdis T, Wilkie EC, et al
    Upregulation of Cellular Palmitoylation Mitigates alpha-Synuclein Accumulation and Neurotoxicity.
    Mov Disord. 2021;36:348-359.
    >> Share

    January 2021
  650. MULLER-NEDEBOCK AC, van der Westhuizen FH, Koks S, Bardien S, et al
    Nuclear Genes Associated with Mitochondrial DNA Processes as Contributors to Parkinson's Disease Risk.
    Mov Disord. 2021 Jan 29. doi: 10.1002/mds.28475.
    >> Share

  651. JEONG SH, Lee HS, Jung JH, Baik K, et al
    White Matter Hyperintensities, Dopamine Loss, and Motor Deficits in De Novo Parkinson's Disease.
    Mov Disord. 2021 Jan 29. doi: 10.1002/mds.28510.
    >> Share


  652. GP2: The Global Parkinson's Genetics Program.
    Mov Disord. 2021 Jan 29. doi: 10.1002/mds.28494.
    >> Share

  653. KIM JJ, Makarious MB, Bandres-Ciga S, Gibbs JR, et al
    The Parkinson's Disease DNA Variant Browser.
    Mov Disord. 2021 Jan 26. doi: 10.1002/mds.28488.
    >> Share

  654. MONJE MHG, Sanchez-Ferro A, Pineda-Pardo JA, Vela-Desojo L, et al
    Motor Onset Topography and Progression in Parkinson's Disease: the Upper Limb Is First.
    Mov Disord. 2021 Jan 20. doi: 10.1002/mds.28462.
    >> Share

  655. DONAHUE EK, Murdos A, Jakowec MW, Sheikh-Bahaei N, et al
    Global and Regional Changes in Perivascular Space in Idiopathic and Familial Parkinson's Disease.
    Mov Disord. 2021 Jan 20. doi: 10.1002/mds.28473.
    >> Share

  656. WELTON T, Tan EK
    Applying Artificial Intelligence to Multi-Omic Data: New Functional Variants in Parkinson's Disease.
    Mov Disord. 2021 Jan 17. doi: 10.1002/mds.28481.
    >> Share

  657. MICHELI F, Vissani M, Pecchioli G, Terenzi F, et al
    Impulsivity Markers in Parkinsonian Subthalamic Single-Unit Activity.
    Mov Disord. 2021 Jan 16. doi: 10.1002/mds.28497.
    >> Share

  658. AVRAM CM, Brumbach BH, Hiller AL
    A Report of Tamoxifen and Parkinson's Disease in a US Population and a Review of the Literature.
    Mov Disord. 2021 Jan 15. doi: 10.1002/mds.28471.
    >> Share

  659. LIN CH, Chang CH, Tai CH, Cheng MF, et al
    A Double-Blind, Randomized, Controlled Trial of Lovastatin in Early-Stage Parkinson's Disease.
    Mov Disord. 2021 Jan 15. doi: 10.1002/mds.28474.
    >> Share

  660. RAVANIDIS S, Bougea A, Karampatsi D, Papagiannakis N, et al
    Differentially Expressed Circular RNAs in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease.
    Mov Disord. 2021 Jan 12. doi: 10.1002/mds.28467.
    >> Share

  661. HERZ DM, Meder D, Camilleri JA, Eickhoff SB, et al
    Brain Motor Network Changes in Parkinson's Disease: Evidence from Meta-Analytic Modeling.
    Mov Disord. 2021 Jan 11. doi: 10.1002/mds.28468.
    >> Share

  662. VILA-VICOSA D, Clemente A, Pona-Ferreira F, Leitao M, et al
    Unsupervised walking activity assessment reveals COVID-19 impact on Parkinson's disease patients.
    Mov Disord. 2021 Jan 11. doi: 10.1002/mds.28514.
    >> Share

  663. ZARKALI A, McColgan P, Leyland LA, Lees AJ, et al
    Visual Dysfunction Predicts Cognitive Impairment and White Matter Degeneration in Parkinson's Disease.
    Mov Disord. 2021 Jan 9. doi: 10.1002/mds.28477.
    >> Share

  664. KUUSIMAKI T, Al-Abdulrasul H, Kurki S, Hietala J, et al
    Increased Risk of Parkinson's Disease in Patients With Schizophrenia Spectrum Disorders.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28484.
    >> Share

  665. CHEN L, Bedard P, Hallett M, Horovitz SG, et al
    Dynamics of Top-Down Control and Motor Networks in Parkinson's Disease.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28461.
    >> Share

  666. SCHIRINZI T, Maftei D, Pieri M, Bernardini S, et al
    Increase of Prokineticin-2 in Serum of Patients with Parkinson's Disease.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28458.
    >> Share

  667. METCALFE-ROACH A, Yu AC, Golz E, Cirstea M, et al
    MIND and Mediterranean Diets Associated with Later Onset of Parkinson's Disease.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28464.
    >> Share

  668. BAUMGARTNER AJ, Press DZ, Simon DK
    The Relationship Between Olfactory Dysfunction and Constipation in Early Parkinson's Disease.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28483.
    >> Share

  669. CHOE CU, Potter-Nerger M, Buhmann C, Blankenberg S, et al
    Reply to: "Parkin Deficiency Appears Not to Be Associated with Cardiac Damage in Parkinson's Disease".
    Mov Disord. 2021;36:273-274.
    >> Share

  670. TRILCK-WINKLER M, Borsche M, Konig IR, Balck A, et al
    Parkin Deficiency Appears Not to Be Associated with Cardiac Damage in Parkinson's Disease.
    Mov Disord. 2021;36:271-273.
    >> Share

  671. WITT K
    The Impact of the Basal Ganglia on Working Memory: Evidence from Parkinson's Disease.
    Mov Disord. 2021;36:13-15.
    >> Share

  672. FULLER RLM, Sanchez-Ferro A, Goetz CG, Martinez-Martin P, et al
    In Support of Electronic Versions of Movement Disorder Society Rating Scales.
    Mov Disord. 2021;36:270-271.
    >> Share

  673. TURNER TH, Dale ML
    Reply to: "In Support of Electronic Versions of Movement Disorder Society Rating Scales".
    Mov Disord. 2021;36:271.
    >> Share

  674. SARANZA G, Lang AE
    Inhaled Levodopa as a Potential Treatment for Diphasic Dyskinesia.
    Mov Disord. 2021;36:265-266.
    >> Share

  675. KIEBURTZ K, Katz R, McGarry A, Olanow CW, et al
    A New Approach to the Development of Disease-Modifying Therapies for PD; Fighting Another Pandemic.
    Mov Disord. 2021;36:59-63.
    >> Share

  676. VIEIRA-YANO B, Martini DN, Horak FB, de Lima-Pardini A, et al
    The Adapted Resistance Training with Instability Randomized Controlled Trial for Gait Automaticity.
    Mov Disord. 2021;36:152-163.
    >> Share

    December 2020
  677. WILSON J, Yarnall AJ, Craig CE, Galna B, et al
    Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease.
    Mov Disord. 2020 Dec 31. doi: 10.1002/mds.28453.
    >> Share

  678. DUITS AA, Boots LMM, Mulders AEP, Moonen AJH, et al
    Covid Proof Self-Management Training for Caregivers of Patients with Parkinson's Disease.
    Mov Disord. 2020 Dec 27. doi: 10.1002/mds.28457.
    >> Share

  679. FILIPPOU P, Outeiro TF
    Cancer and Parkinson's Disease: Common Targets, Emerging Hopes.
    Mov Disord. 2020 Dec 21. doi: 10.1002/mds.28425.
    >> Share

  680. NISSEN SK, Ferreira SA, Nielsen MC, Schulte C, et al
    Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease.
    Mov Disord. 2020 Dec 17. doi: 10.1002/mds.28424.
    >> Share

  681. ZOON TJC, van Rooijen G, Balm GMFC, Bergfeld IO, et al
    Apathy Induced by Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease: A Meta-Analysis.
    Mov Disord. 2020 Dec 16. doi: 10.1002/mds.28390.
    >> Share

  682. SKRAHINA V, Gaber H, Vollstedt EJ, Forster TM, et al
    The Rostock International Parkinson's Disease (ROPAD) Study: Protocol and Initial Findings.
    Mov Disord. 2020 Dec 14. doi: 10.1002/mds.28416.
    >> Share

  683. KLINE EM, Houser MC, Herrick MK, Seibler P, et al
    Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation.
    Mov Disord. 2020 Dec 14. doi: 10.1002/mds.28411.
    >> Share

  684. ELFIL M, Bahbah EI, Attia MM, Eldokmak M, et al
    Impact of Obstructive Sleep Apnea on Cognitive and Motor Functions in Parkinson's Disease.
    Mov Disord. 2020 Dec 9. doi: 10.1002/mds.28412.
    >> Share

  685. MULLIN S, Stokholm MG, Hughes D, Mehta A, et al
    Brain Microglial Activation Increased in Glucocerebrosidase (GBA) Mutation Carriers without Parkinson's disease.
    Mov Disord. 2020 Dec 5. doi: 10.1002/mds.28375.
    >> Share

  686. CAREY G, Gormezoglu M, de Jong JJA, Hofman PAM, et al
    Neuroimaging of Anxiety in Parkinson's Disease: A Systematic Review.
    Mov Disord. 2020 Dec 2. doi: 10.1002/mds.28404.
    >> Share

  687. OLSZEWSKA DA, Lang AE
    "Opening" New Insights Into LRRK2 Conformation and the Microtubule.
    Mov Disord. 2020;35:2162-2163.
    >> Share

    November 2020
  688. MARTIN WRW, Miles M, Zhong Q, Hartlein J, et al
    Is Levodopa Response a Valid Indicator of Parkinson's Disease?
    Mov Disord. 2020 Nov 30. doi: 10.1002/mds.28406.
    >> Share

  689. GUTTLER C, Altschuler J, Tanev K, Bockmann S, et al
    Levodopa-Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
    Mov Disord. 2020 Nov 28. doi: 10.1002/mds.28403.
    >> Share

  690. PORTLEY MK, Scholz SW
    Hot Topic: Epigenetics in Parkinson's Disease: A New Frontier for Disease-Modifying Therapies.
    Mov Disord. 2020 Nov 27. doi: 10.1002/mds.28410.
    >> Share

  691. SANTOS-GARCIA D, Pozojevic J, de Deus Fonticoba T, Kurtis M, et al
    First Case of Parkinsonian-Pyramidal Syndrome Associated with a TBK1 Mutation.
    Mov Disord. 2020 Nov 27. doi: 10.1002/mds.28405.
    >> Share

  692. WALDTHALER J, Stock L, Sommerkorn J, Kruger-Zechlin C, et al
    Antisaccade Latency Is Sensitive to Longitudinal Change of Motor and Cognitive Symptoms in Parkinson's Disease.
    Mov Disord. 2020 Nov 25. doi: 10.1002/mds.28374.
    >> Share

  693. AL-QASSABI A, Tsao TS, Racolta A, Kremer T, et al
    Immunohistochemical Detection of Synuclein Pathology in Skin in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinsonism.
    Mov Disord. 2020 Nov 24. doi: 10.1002/mds.28399.
    >> Share

  694. JAAKKOLA E, Huovinen A, Kaasinen V, Joutsa J, et al
    No Change in Prevalence of Impulse Control Disorder Behaviors in Parkinson's Disease During the Last Decade.
    Mov Disord. 2020 Nov 24. doi: 10.1002/mds.28400.
    >> Share

  695. GARCIA-SANZ P, M F G Aerts J, Moratalla R
    The Role of Cholesterol in alpha-Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease.
    Mov Disord. 2020 Nov 21. doi: 10.1002/mds.28396.
    >> Share

  696. PAGAN FL, Wilmarth B, Torres-Yaghi Y, Hebron ML, et al
    Long-Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease.
    Mov Disord. 2020 Nov 20. doi: 10.1002/mds.28389.
    >> Share

  697. ERREA O, Rodriguez-Oroz MC
    Oligodendrocytes, a New Player in the Etiology of Parkinson's Disease.
    Mov Disord. 2020 Nov 18. doi: 10.1002/mds.28393.
    >> Share

  698. OJUKWU DI, Andruska KM, Halpern CH
    Lessons From George Floyd: Racial Inequalities in the Treatment of Parkinson's Disease.
    Mov Disord. 2020 Nov 17. doi: 10.1002/mds.28388.
    >> Share

  699. ISHIBASHI K, Miura Y, Wagatsuma K, Toyohara J, et al
    Adenosine A2A Receptor Occupancy by Long-Term Istradefylline Administration in Parkinson's Disease.
    Mov Disord. 2020 Nov 16. doi: 10.1002/mds.28378.
    >> Share

  700. OUTEIRO TF, Heutink P, Bezard E, Cenci AM, et al
    From iPS Cells to Rodents and Nonhuman Primates: Filling Gaps in Modeling Parkinson's Disease.
    Mov Disord. 2020 Nov 16. doi: 10.1002/mds.28387.
    >> Share

  701. VIGNATELLI L, Zenesini C, Belotti LMB, Baldin E, et al
    Risk of hospitalization and death for COVID-19 in people with Parkinson's disease or parkinsonism.
    Mov Disord. 2020 Nov 16. doi: 10.1002/mds.28408.
    >> Share

  702. MAETZLER W, Rochester L, Bhidayasiri R, Espay AJ, et al
    Modernizing Daily Function Assessment in Parkinson's Disease Using Capacity, Perception, and Performance Measures.
    Mov Disord. 2020 Nov 15. doi: 10.1002/mds.28377.
    >> Share

  703. DEVOS D, Hirsch E, Wyse R
    Seven Solutions for Neuroprotection in Parkinson's Disease.
    Mov Disord. 2020 Nov 13. doi: 10.1002/mds.28379.
    >> Share

  704. DE MICCO R, Satolli S, Siciliano M, Di Nardo F, et al
    Connectivity Correlates of Anxiety Symptoms in Drug-Naive Parkinson's Disease Patients.
    Mov Disord. 2020 Nov 10. doi: 10.1002/mds.28372.
    >> Share

  705. PICILLO M, Phokaewvarangkul O, Poon YY, McIntyre CC, et al
    Levodopa Versus Dopamine Agonist After Subthalamic Stimulation in Parkinson's Disease.
    Mov Disord. 2020 Nov 9. doi: 10.1002/mds.28382.
    >> Share

  706. QUATTRONE A, Antonini A, Vaillancourt DE, Seppi K, et al
    A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study.
    Mov Disord. 2020 Nov 5. doi: 10.1002/mds.28364.
    >> Share

  707. SARIHAN EI, Perez-Palma E, Niestroj LM, Loesch D, et al
    Genome-Wide Analysis of Copy Number Variation in Latin American Parkinson's Disease Patients.
    Mov Disord. 2020 Nov 5. doi: 10.1002/mds.28353.
    >> Share

  708. VAN DER ZEE S, Muller MLTM, Kanel P, van Laar T, et al
    Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease.
    Mov Disord. 2020 Nov 2. doi: 10.1002/mds.28360.
    >> Share

  709. CHOUGAR L, Faouzi J, Pyatigorskaya N, Yahia-Cherif L, et al
    Automated Categorization of Parkinsonian Syndromes Using Magnetic Resonance Imaging in a Clinical Setting.
    Mov Disord. 2020 Nov 2. doi: 10.1002/mds.28348.
    >> Share

  710. DORSEY ER, Bloem BR, Okun MS
    A New Day: The Role of Telemedicine in Reshaping Care for Persons With Movement Disorders.
    Mov Disord. 2020;35:1897-1902.
    >> Share

  711. HERRINGTON TM, Schweitzer J, Henchcliffe C, Carter BS, et al
    Toward a Personalized Approach to Parkinson's Cell Therapy.
    Mov Disord. 2020;35:2119-2120.
    >> Share

  712. SILVA-BATISTA C, M Corcos D, B Horak F, Ugrinowitsch C, et al
    Reply to: 'Letter to the Editor on "A Randomized Controlled Trial of Exercise for Parkinsonian Individuals With Freezing of Gait"'.
    Mov Disord. 2020;35:2123-2124.
    >> Share

  713. KORDOWER JH, Okun MS, Jankovic J
    Reply to: "Toward a Personalized Approach to Parkinson's Cell Therapy".
    Mov Disord. 2020;35:2120-2121.
    >> Share

  714. NONNEKES J, Gilat M, D'Cruz N, Dijkstra BW, et al
    Letter to the Editor on "A Randomized, Controlled Trial of Exercise for Parkinsonian Individuals With Freezing of Gait".
    Mov Disord. 2020;35:2122-2123.
    >> Share

    October 2020
  715. TAN MMX, Lawton MA, Jabbari E, Reynolds RH, et al
    Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease.
    Mov Disord. 2020 Oct 28. doi: 10.1002/mds.28342.
    >> Share

  716. SUN YM, Yu HL, Zhou XY, Xiong WX, et al
    Disease Progression in Patients with Parkin-Related Parkinson's Disease in a Longitudinal Cohort.
    Mov Disord. 2020 Oct 27. doi: 10.1002/mds.28349.
    >> Share

  717. MENOZZI E, Macnaughtan J, Schapira AHV
    LRRK2 Parkinsonism: Does the Response to Gut Bacteria Mitigate the Neurological Picture?
    Mov Disord. 2020 Oct 27. doi: 10.1002/mds.28347.
    >> Share

  718. VAN DEN HEUVEL L, Evers L, Meinders M, Post B, et al
    Estimating the Effect of Early Treatment Initiation in Parkinson's Disease Using Observational Data.
    Mov Disord. 2020 Oct 27. doi: 10.1002/mds.28339.
    >> Share

  719. BEYLERGIL SB, Petersen M, Gupta P, Elkasaby M, et al
    Severity-Dependent Effects of Parkinson's Disease on Perception of Visual and Vestibular Heading.
    Mov Disord. 2020 Oct 26. doi: 10.1002/mds.28352.
    >> Share

  720. YE Z, Zhang G, Zhang Y, Li S, et al
    The Role of the Subthalamic Nucleus in Sequential Working Memory in De Novo Parkinson's Disease.
    Mov Disord. 2020 Oct 24. doi: 10.1002/mds.28344.
    >> Share

  721. VAN DER HEIDE A, Meinders MJ, Speckens AEM, Peerbolte TF, et al
    Stress and Mindfulness in Parkinson's Disease: Clinical Effects and Potential Underlying Mechanisms.
    Mov Disord. 2020 Oct 23. doi: 10.1002/mds.28345.
    >> Share

  722. FU JF, Matarazzo M, McKenzie J, Neilson N, et al
    Serotonergic System Impacts Levodopa Response in Early Parkinson's and Future Risk of Dyskinesia.
    Mov Disord. 2020 Oct 22. doi: 10.1002/mds.28340.
    >> Share

  723. YIN W, Lof M, Pedersen NL, Sandin S, et al
    Mediterranean Dietary Pattern at Middle Age and Risk of Parkinson's Disease: A Swedish Cohort Study.
    Mov Disord. 2020 Oct 20. doi: 10.1002/mds.28314.
    >> Share

  724. TAKEDA A, Takahashi R, Tsuboi Y, Nomoto M, et al
    Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients With Motor Fluctuations.
    Mov Disord. 2020 Oct 19. doi: 10.1002/mds.28322.
    >> Share

  725. LOWES H, Robertson F, Pyle A, Hussain R, et al
    The human coronavirus receptor ANPEP (CD13) is overexpressed in Parkinson's disease.
    Mov Disord. 2020 Oct 18. doi: 10.1002/mds.28354.
    >> Share

  726. SCHLOSSMACHER MG, Graybiel AM
    Conversations With Dr. Oleh Hornykiewicz, Founding Father of the Dopamine Era in Parkinson's: How Do You Wish to Be Remembered?
    Mov Disord. 2020 Oct 14. doi: 10.1002/mds.28316.
    >> Share

  727. TAKAMIYA A, Seki M, Kudo S, Yoshizaki T, et al
    Electroconvulsive Therapy for Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Mov Disord. 2020 Oct 14. doi: 10.1002/mds.28335.
    >> Share

  728. MESTRE TA, Kessler D, Cote D, Liddy C, et al
    Pilot Evaluation of a Pragmatic Network for Integrated Care and Self-Management in Parkinson's Disease.
    Mov Disord. 2020 Oct 14. doi: 10.1002/mds.28332.
    >> Share

  729. BELVISI D, Fabbrini A, De Bartolo MI, Costanzo M, et al
    The Pathophysiological Correlates of Parkinson's Disease Clinical Subtypes.
    Mov Disord. 2020 Oct 10. doi: 10.1002/mds.28321.
    >> Share

  730. DAHODWALA N, Li P, Jahnke J, Ladage VP, et al
    Burden of Parkinson's Disease by Severity: Health Care Costs in the U.S. Medicare Population.
    Mov Disord. 2020 Oct 8. doi: 10.1002/mds.28265.
    >> Share

  731. SANTIN MDN, Voulleminot P, Vrillon A, Hainque E, et al
    Impact of Subthalamic Deep Brain Stimulation on Impulse Control Disorders in Parkinson's Disease: A Prospective Study.
    Mov Disord. 2020 Oct 6. doi: 10.1002/mds.28320.
    >> Share

  732. ISRAEL Z, Asch N
    Reversing a Model of Parkinson's Disease With In Situ Converted Nigral Neurons.
    Mov Disord. 2020 Oct 5. doi: 10.1002/mds.28306.
    >> Share

  733. BONVEGNA S, Straccia G, Golfre Andreasi N, Elia AE, et al
    Parkinsonism and Nigrostriatal Damage Secondary to CSF1R-Related Primary Microgliopathy.
    Mov Disord. 2020 Oct 3. doi: 10.1002/mds.28290.
    >> Share

  734. KANE PB, Benjamin DM, Barker RA, Lang AE, et al
    Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease.
    Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28319.
    >> Share

  735. TSUBOI T, Charbel M, Peterside DT, Rana M, et al
    Pallidal Connectivity Profiling of Stimulation-Induced Dyskinesia in Parkinson's Disease.
    Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28324.
    >> Share

  736. IWAKI H, Blauwendraat C, Leonard HL, Makarious MB, et al
    Differences in the Presentation and Progression of Parkinson's Disease by Sex.
    Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28312.
    >> Share

  737. MUFTI K, Rudakou U, Yu E, Krohn L, et al
    Comprehensive Analysis of Familial Parkinsonism Genes in Rapid-Eye-Movement Sleep Behavior Disorder.
    Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28318.
    >> Share

  738. ACHBANI A, Sine H, Naciri A, Baba MA, et al
    Reply to: "Can the 2019 Novel Coronavirus Cause Parkinson's Disease?"
    Mov Disord. 2020;35:1726.
    >> Share

  739. HURWITZ B, Lees AJ, Walusinski O
    Light and Shade in Patrick Lewis et al's Paper on the First Photographs of Parkinson's Disease.
    Mov Disord. 2020;35:1880-1881.
    >> Share

  740. SULLIVAN R, Yau WY, Chelban V, Rossi S, et al
    Dopa-Responsive Parkinsonism in a Patient With Homozygous RFC1 Expansions.
    Mov Disord. 2020;35:1890-1891.
    >> Share

  741. DA SILVA SCHMITT G, Martinez ARM, da Graca FF, de Lima FD, et al
    Dopa-Responsive Parkinsonism in a Patient With Homozygous RFC1 Expansions.
    Mov Disord. 2020;35:1889-1890.
    >> Share

  742. AGUIRRE-PADILLA DH, Lozano AM, Fasano A
    Reply to: "Spinal Cord Stimulation for Parkinson's Disease: Dynamic Habituation as a Mechanism of Failure?"
    Mov Disord. 2020;35:1883.
    >> Share

  743. MONTGOMERY EB JR
    Debugging Adaptive Deep Brain Stimulation for Parkinson's Disease.
    Mov Disord. 2020;35:1891.
    >> Share

  744. CURY RG, Carra RB, Capato TTC, Teixeira MJ, et al
    Spinal Cord Stimulation for Parkinson's Disease: Dynamic Habituation as a Mechanism of Failure?
    Mov Disord. 2020;35:1882-1883.
    >> Share

  745. MONJE MHG, Martinez-Fernandez R
    Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Parkinsonism: Is There Evidence for Concern?
    Mov Disord. 2020;35:1725.
    >> Share

  746. ALVES M, Caldeira D, Reimao S, Ferro JM, et al
    N-Terminal Pro-B-Type Natriuretic Peptide Levels in Parkinson's Disease.
    Mov Disord. 2020;35:1886-1887.
    >> Share

  747. CHOE CU, Petersen E, Potter-Nerger M, Buhmann C, et al
    Reply to: "N-Terminal Pro-B-Type Natriuretic Peptide Levels in Parkinson's Disease".
    Mov Disord. 2020;35:1888.
    >> Share

  748. LEWIS PA, Plun-Favreau H, Rowley M, Spillane J, et al
    Reply to: "Light and Shade in Patrick Lewis et al's Paper on the First Photographs of Parkinson's Disease".
    Mov Disord. 2020;35:1882.
    >> Share

  749. CROTTY GF, Lo RY, Schwarzschild MA
    If LRRK2 Set the Fire, Can Nonsteroidal Anti-inflammatory Drugs Wet the Flames?
    Mov Disord. 2020;35:1727-1730.
    >> Share

    September 2020
  750. BLUMENREICH S, Jenkins BJ, Barav OB, Milenkovic I, et al
    The Lysosome and Nonmotor Symptoms: Linking Parkinson's Disease and Lysosomal Storage Disorders.
    Mov Disord. 2020 Sep 28. doi: 10.1002/mds.28232.
    >> Share

  751. RAJPUT AH, Kish SJ
    Professor Oleh Hornykiewicz, MD (1926-2020): Remembering the Father of the Modern Treatment of Parkinson's Disease and the Man.
    Mov Disord. 2020 Sep 28. doi: 10.1002/mds.28317.
    >> Share

  752. AL ALI J, Vaine CA, Shah S, Campion L, et al
    TAF1 Transcripts and Neurofilament Light Chain as Biomarkers for X-Linked Dystonia-Parkinsonism.
    Mov Disord. 2020 Sep 25. doi: 10.1002/mds.28305.
    >> Share

  753. ZHANG X
    Comment on "Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease".
    Mov Disord. 2020;35:1695.
    >> Share

  754. LU C, Amundsen Huffmaster SL, Louie KH, Sovell-Brown K, et al
    Pallidal Oscillation Dynamics Following Cessation of Deep Brain Stimulation in Parkinson's Disease.
    Mov Disord. 2020;35:1697-1698.
    >> Share

  755. SPEECKAERT MM, Speeckaert R, Delanghe JR
    Standardized 25-Hydroxyvitamin D Measurements in Parkinson's Disease Patients With COVID-19.
    Mov Disord. 2020;35:1497.
    >> Share

  756. CIRSTEA MS, Yu AC, Golz E, Sundvick K, et al
    Reply to: 'Comment on "Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease"'.
    Mov Disord. 2020;35:1695-1697.
    >> Share

  757. NEUMANN WJ, Feldmann L, Kuhn AA
    Reply to: Pallidal Low-Frequency Activity in Dystonia and Subthalamic Beta Activity in Parkinson's Disease.
    Mov Disord. 2020;35:1699.
    >> Share

  758. CEREDA E, Fasano A, Pezzoli G
    Reply to: Standardized 25-Hydroxyvitamin D Measurements in Parkinson's Disease Patients With COVID-19.
    Mov Disord. 2020;35:1498.
    >> Share

  759. WEIL RS
    Visual Dysfunction and Parkinson's Disease.
    Mov Disord. 2020;35:1499-1501.
    >> Share

    August 2020
  760. MARKAKI I, Bergstrom S, Tsitsi P, Remnestal J, et al
    Cerebrospinal Fluid Levels of Kininogen-1 Indicate Early Cognitive Impairment in Parkinson's Disease.
    Mov Disord. 2020 Aug 15. doi: 10.1002/mds.28192.
    >> Share

    July 2020
  761. LERCHE S, Wurster I, Roben B, Zimmermann M, et al
    CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories.
    Mov Disord. 2020;35:1138-1144.
    >> Share

    February 2020
  762. MAHATO AK, Kopra J, Renko JM, Visnapuu T, et al
    Glial cell line-derived neurotrophic factor receptor Rearranged during transfection agonist supports dopamine neurons in Vitro and enhances dopamine release In Vivo.
    Mov Disord. 2020;35:245-255.
    >> Share

  763. RAPPEL P, Grosberg S, Arkadir D, Linetsky E, et al
    Theta-alpha oscillations characterize emotional subregion in the human ventral subthalamic nucleus.
    Mov Disord. 2020;35:337-343.
    >> Share

  764. MARTINEZ E, Pasquereau B, Saga Y, Metereau E, et al
    The anterior caudate nucleus supports impulsive choices triggered by pramipexole.
    Mov Disord. 2020;35:296-305.
    >> Share

  765. LEE JY, Ahn J, Oh S, Shin JY, et al
    Retina thickness as a marker of neurodegeneration in prodromal lewy body disease.
    Mov Disord. 2020;35:349-354.
    >> Share

    January 2020
  766. BELLOMO G, Paciotti S, Gatticchi L, Parnetti L, et al
    The vicious cycle between alpha-synuclein aggregation and autophagic-lysosomal dysfunction.
    Mov Disord. 2020;35:34-44.
    >> Share

  767. PYATIGORSKAYA N, Yahia-Cherif L, Gaurav R, Ewenczyk C, et al
    Multimodal Magnetic Resonance Imaging Quantification of Brain Changes in Progressive Supranuclear Palsy.
    Mov Disord. 2020;35:161-170.
    >> Share

  768. COUGHLIN DG, Hurtig HI, Irwin DJ
    Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases.
    Mov Disord. 2020;35:5-19.
    >> Share

  769. CHAUDHURI KR, Schrag A, Weintraub D, Rizos A, et al
    The movement disorder society nonmotor rating scale: Initial validation study.
    Mov Disord. 2020;35:116-133.
    >> Share

  770. RESPONDEK G, Grimm MJ, Piot I, Arzberger T, et al
    Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies.
    Mov Disord. 2020;35:171-176.
    >> Share

  771. ALCALAY RN, Hsieh F, Tengstrand E, Padmanabhan S, et al
    Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development.
    Mov Disord. 2020;35:134-141.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016